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ABBREVIATIONS 
AA amino acid 
ACN acetonitrile 
Aic 2-aminoindane-2-carboxylic acid 
At aminotetralin 
Ate 2-aminotetralin-2-carboxylic acid 
Bmax maximum number of binding sites 
BBB blood-brain barrier 
Boc N-/er/-butoxycarbonyl 
Boc20 di-/er/-butyl dicarbonate 
Bop benzotriazol-1 -yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate 
Bzl benzyl 
Cha cyclohexylalanine 
Chloramine-T A-chloro-p-toluenesulfonamide 
DADLE H-Tyr-D-Ala-Gly-Phe-D-Leu-OH 
DAMGO H-Tyr-jD-Ala-Gly- N(Me)Phe-Gly-ol 
DCC dicyclohexylcarbodiimide 
DCM dichloromethane 
DCU dicyclohexylurea 
Deltorphin I H-Tyr-£>-Ala-Phe-Asp-Val-Val-Gly-NH2 
Deltorphin II H-Tyr-Z>-Ala-Phe-Glu-Val-Val-Gly-NH2 
DIEA N.N-diisopropylethylamine 
DIPCDI diisopropylcarbodiimide 
DIPP H-Dmt-Tic-Phe-Phe-OH 
DIPP-NH2 H-Dmt-Tic-Phe-Phe-NH2 
DIPP [lP]-NH2 H-Dmt-Tic[CH2-NH] -Phe-Phe-NH2 
Dit 3\5'-diiodotyrosine 
DMF . N,N-dimethylformamide 
DMS dimethyl sulfide 
DMSO dimethyl sulfoxide 
Dmt 2'6'-dimethyltyrosine 
DNA deoxyribonucleic acid 
DPDPE H-Tyr-c[D-Pen-Gly-Phe-D-Pen]-OH 
DSLET H-Tyr-D-Ser-Gly-Phe-Leu-Thr-OH 
DTLET H-Tyr-D-Thr-Gly-Phe-Leu-Thr-OH 
EDT 1,2-ethanedithiol 
EKC ethylketocyclazocine 
EtOAc ethyl acetate 
FDAA Marfey's reagent s l-fluoro-2,4-dinitrophenyl-5-L-alanine amide 
Fmoc 9-fluorenylmethoxycarbonyl 
GlTC 2,3,4,6-tetra-0-acetyl-P-Z)-glucopyranosyl isothiocyanate 
GPI guinea pig ileum 
GTPyS guanosine-5'-0-(3-thio)triphosphate 
Hat 6-hydroxy-2-aminotetralin-2-carboxylic acid 
H-otDmt-OH 2-methylamino-3-(2'6'-dimethyl-4-hydroxyphenyl)propionic acid 
H-J3Tic l,2,3,4-tetrahydroisoquinoline-3-yl acetic acid 
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HBTU 2-( 1 H-benzotriazol-1 -yl)-1,1,3,3 -tetramethyluronium hexafluorophosphate 
Hfe homophenylalanine 
Hmt 2'-hydroxy-6' -methyltyrosine 
HOBt 1 -hydroxybenzotriazole 
RP-HPLC reversed-phase high-performance liquid chromatography 
IC50 the ligand concentration that inhibits specific radioligand binding by 50% 
k' capacity factor 
Kd equilibrium dissociation constant 
Ke the molar concentration required to double the agonist concentration to achieve 
the original response 
Ki equilibrium inhibitory constant 
LSC liquid scintillation counter 
MBHA resin 4-methylbenzhydrylamine resin 
p-MePhe P-methyl-phenylalanine 
MeTic L-3-methyl-l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
MVD mouse vas deferens 
2-Nal 3 -(2 ' -naphthyl)alanine 
Nva norvaline 
Orn ornithine 
Ph phenyl 
Phe(pN02) /rarra-nitrophenylalanine 
PyBOPbenzotriazol-1 -yl-oxy-tris(pyrrolidino)phosphonium hexafluorophosphate 
PyBrOP bromo-tris(pyrrolidino)phosphonium hexafluorophosphate 
RT room temperature 
SPPS solid-phase peptide synthesis 
t-Bu /er/-butyl 
TBTU 2-( 1 H-benzotriazol-1 -yl)-1,1,3,3 -tetramethyluronium tetrafluoroborate 
TEA triethylamine 
TFA trifluoroacetic acid 
TFMSA trifluoromethanesulfonic acid 
Tia l,2,3,4-tetrahydroisoquinoline-3-amine 
TIA thioanisole 
Tic 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
TICP H-Tyr-Tic-Cha-Phe-OH 
T I C P ^ ] H-Tyr-Tic[CH2-NH]-Cha-Phe-OH 
TIP H-Tyr-Tic-Phe-OH 
TIP[*F] H-Tyr-Tic[CH2-NH]-Phe-OH 
TDPP H-Tyr-Tic-Phe-Phe-OH 
TIPP-NHa H-Tyr-Tic-Phe-Phe-NH2 
TEPPfT] H-Tyr-Tic[CH2-NH]-Phe-Phe-OH 
TNBS 2,4,6-trinitrobenzenesulfonic acid 
TLC thin-layer chromatography 
U-69593 (5a,7a,8P)-N-methyl-[7-(l-pyrrolidinyl)-l-oxaspiro-[4,5]dec-8-yl]-
benzeneacetamide 
Z benzyloxycarbonyl 
iii 
LIST OF PUBLICATIONS RELATED TO THE THESIS 
[I] I. Kertész, G. Balboni, S. Salvadori, L. H. Lazarus G. Tóth, Synthesis of 2',6'-
dimethyltyrosine containing tritiated delta opioid-receptor selective antagonist dipeptide 
ligands with extraordinary affinity, J. Lab. Comp. andRadiopharm. 41 (1998) p. 1083-1091 
[II] D. Tourwe, E. Mannekens, T.D. Nguyen, P. Verheyden, H. Jaspers, G. Tóth, A. Péter, 
I. Kertész, G. Török, N.N. Chung, P.W. Schiller, Sidechain methyl substitution in the delta 
opioid-receptor antagonist TIPP has an important effect on the activity profile, J. Med Chem. 
41(1998) p. 5167-5176 
[ID] I. Kertész, G. Tóth, G. Balboni, R. Guerrini, S. Salvadori, Tritiation of delta opioid-
receptor selective antagonist dipeptide ligands with extraordinary affinity containing 
2',6'-dimethyltyrosine, Czech. J. Phys. 49 (1999) p. 887-892 
[TV] I. Szatmári, G. Tóth,, I. Kertész, P.W. Schiller, A. Borsodi, Synthesis and binding 
characteristics of [3H]H-Tyr-TicT/[CH2-NH]-Cha-Phe-OH, a highly specific and stable 8-
opioid antagonist, Peptides 20 (1999) p. 1079-1083 
[V] K. Monory, S.D. Bryant, I. Kertész, G. Balboni, R. Guerrini, G.Tóth, S. Salvadori, 
L.H. Lazarus, A. Borsodi, Characterization of N,N(Me)2-Dmt-Tic-OH, a delta selective opioid 
dipeptide antagonist, Neuroreport 10 (2000) p. 2083-2086. 
iv 
ACKNOWLEDGEMENTS 
I would like to thank my supervisor, Dr. Géza Tóth, for giving me the opportunity to perform 
this work in the isotope laboratory and for all his help during these years. 
I am also grateful to Prof. Peter Schiller, Prof. Dirk Tourwé and Prof. Severo Salvadori for 
helping me to join in with their research in the opioid field. 
My thanks are also due to all my colleagues in the laboratory for their useful advice and 
technical assistance. 
I would like to thank Dr. Krisztina Monory and Dr. Ildikó Szatmári for radioligand 
characterization. 
I am grateful to Dr. József Környei, Dr. Gábor Tóth and Dr. Sándor Benyhe for carefully 
reading this dissertation and for their valuable criticisms and suggestions. 
For financial support, I wish to thank the SzETE Ph.D. programme. 
V 
TABLE OF CONTENTS 
1. INTRODUCTION 1 
1.1. The opioid receptor and opioid peptides 1 
1.1.1. The opioid receptor 1 
1.1.2. Opioid peptides 3 
1.2. Synthesis of amino acids 12 
1.3. Separation of enantiomeric amino acids 13 
1.3.1. Resolution of amino acids on a preparative scale 13 
1.3.2. Resolution of amino acids on an analytical scale 14 
1.4. Solid-phase peptide synthesis 14 
1.5. Tritium labelling of peptides 16 
2. AIMS AND SCOPE 18 
3. MATERIALS AND METHODS 19 
4. RESULTS AND DISCUSSION 27 
4.1. Synthesis 27 
4.2. Biological data 35 
4.2.1. fi-Methyl amino acid substituted TIPP analogues. 35 
4.2.2. Binding characteristics of fHJTICPtP] and (sH]N,N(Me)2-Dmt-Tic-OH 38 
5. SUMMARY 43 
6. REFERENCES. 45 
1 
I. INTRODUCTION 
1.1. The opioid receptor and opioid peptides 
1.1.1. The opioid receptor 
Pain is a highly subjective, unique sensation. Opium has been extracted from the poppy 
plant and used to treat pain for thousands of years but with little understanding of its 
mechanism of action. Besides its analgesic effect, opium has several side-effects, among others 
mood changes, which are the basis of its non-medical use and of its abuse. The major active 
ingredient of opium is the alkaloid morphine, which was isolated from it by Friedrich Sertürner 
in 1805. Unfortunately, it proved to be as addictive as opium, also causing respiratory 
depression, which is the main limit to the clinical use of morphine. Despite the major advances 
in our understanding of the actions of opiates and the synthesis of hundreds of analogues, 
morphine remains one of the most widely used analgesics. The various discoveries have 
prompted biologists to find the mechanism of action of morphine in the human body, and 
chemists to develop more efficacious and safe drugs. 
During World War II, Beecher observed that wounded soldiers required far less drug, 
despite the greater severity of their wounds, as compared with civilians, implying that they felt 
less pain [1], He concluded that situational factors, such as the stress of combat, can modify 
the perception of pain. This study illustrated the lack of a clear correlation between the 
nociceptive input and the perception of pain. Recent studies have identified a pain modulatory 
system within the brain that may explain these observations. The fact that the analgesia is 
reversible by the specific opioid antagonist naloxone [2] implied the presence of an endogenous 
opioid system within the brain containing morphine-like factors. Opiates mimic the actions of 
these naturally occurring peptides. 
Opiate receptors were first hypothesized in 1954 [3], almost 20 years before they were 
demonstrated experimentally in 1973 [4-6], Opiate receptors consist seven transmembrane 
segments and interact with heterotrimeric G-proteins. Ligands acting on the receptors are 
named 'agonists' while compounds that inhibit the actions of agonists are called 'antagonists'. 
The first indication of multiple types came from studies of the interactions of morphine and 
nalorphine [7,8], which led Martin to propose the concept of "receptor dualism" [9], 
Subsequently, he extended his classification and, on the basis of behavioral and 
neurophysiology observations on the chronic spinal dog, three different opioid receptors 
were distinguished [10] and named after the drugs used in the test: mu (p, from morphine), 
kappa (K, from ketocyclazocine) and sigma (a, from SKF 10047 or N-allylnormetazocine). 
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Later, the o-receptor proved to be non-opioid, and another type of opioid receptor, the delta 
(8-receptor) was described by Lord et al. [11] on the basis of results of bioassays carried out 
on peripheral tissue preparations. The development of a potent antagonist for any peptide 
hormone or neurotransmitter is of great importance for studies aimed at elucidating its 
physiological role. In a situation of receptor heterogeneity, antagonists with selectivity for each 
receptor type are valuable pharmacological tools and may also have potential as therapeutic 
agents. Later, pi- and p2-receptor subtypes were suggested to explain the binding property of 
the p-receptor [12]. Computer modelling programmes soon confirmed the presence of two 
morphine receptor subtypes [13], Rothman came to a similar conclusion with his mu-delta 
complex, which corresponds to the pi-receptor [14]. While pi- and p2-receptors bind 
morphine quite well, their overall selectivities for other classes of opioids and opioid peptides 
differ significantly. Although their general distributions within the brain are somewhat similar, 
significant differences exist [15,16]. In the early 90s, the heterogeneity of the 8-receptor was 
suggested on the basis of pharmacological investigations. These studies showed that the effects 
of different S-agonists are blocked unevenly by different, highly selective 8-antagonist ligands 
[17-20], Two subtypes, the 8j- and 82-receptors were distinguished. 7-Benzylidenenaltrexone 
[21] is a selective antagonist of the Si subtype. Non-equlibrium antagonists of the S2-receptor 
are naltrindole-5'-isothiocyanate [22] and naltribene [17], DPDPE is a selevtive Si-agonist, 
while deltorphin II is a selective agonist of the 82-receptor. However, these pharmacologically 
defined subtypes have not been identified at a molecular level to date. Devi et al. [23] provided 
biochemical and pharmacological evidence for the heterodimerization of two fully functional 
opioid receptors, k and 8. This results in a new receptor that exhibits ligand binding and 
functional properties that are distinct from those of either receptor. 
Molecular biology approaches have also been applied to demonstrate the existence of 
% 
opioid receptors. In the early 90s, cloning of the opioid receptor cDNAs was reported by 
different groups [24-27], The binding and functional properties of the cloned receptors are 
identical with those described by pharmacological experiments for the p-, 8- and K-receptors. 
.Recently, mice lacking the p-opioid receptor were generated by two independent laboratories 
[28,29], Experiments performed on these animals proved that all the beneficial and non-desired 
effects of morphine are mediated in vivo exclusively by the p-receptors. Therefore, drugs 
targeting this receptor are not likely to provide the ideal analgesic drug. K-Opioid agonists 
have been shown to be potent analgesics, but, unfortunately, they also cause psychotomimetic 
and dysphoric effects. Since p- and K-opiates produce many of their side-effects via interaction 
with central opioid receptors, the current focus is on developing them as peripherally rather 
than centrally acting analgesics. Thus, ligands acting on the 8-receptors are of great interest. 
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There is a functional interaction between p.- and 5-receptors [30]. The p "knockout" mice 
provided a means of investigating whether analgesia mediated by 5-receptors is maintained in 
the absence of p-receptors. These investigations led to an ambiguous conclusion. Spinal and 
supraspinal analgesia evoked by deltorphin II [31] and DPDPE [31-33] was reported to be 
slightly less [31], unchanged [32], or drastically reduced [33] in the p-receptor-deficient mice. 
Biochemical pathways activated by 5-agonists, G-protein activation and the inhibition of 
adenylate cyclase were retained in the p-knockout mice. These data emphasize that 
antinociception mediated by 5-receptors is at least in part independent of the p-receptors. This 
confirms that highly potent 5-agonists could gain clinical importance. 
1.1.2. Opioid peptides 
The opioid peptides are formed in the brain, the pituitary gland and the adrenal medulla 
by the proteolytic cleavage of three protein precursors. In mammals, three such precursors are 
known: proenkephalin A [34], which gives rise to enkephalins and related peptides; 
prodynorphine [35], from which dynorphins and neoendorphins are formed; and 
proopiomelanocortin [36] from which, amongst other hormonally active peptides, 3-endorphin 
is formed. The primary structures of these precursors, each of which has approximately 260 
amino acid residues, have been determined by the use of recombinant DNA techniques [37,38], 
Enkephalins, the first discovered endogenous opioid ligands which act on the 5-receptors, were 
described in the mid-70s [39], The dynorphins are generally acknowledged to be the 
endogenous ligands for the K-receptors [40], P-Endorphin was regarded as the possible 
endogenous ligand of the p-receptor before the discovery of endomorphins [41]. The 
discovery of the endomorphin family, the endogenous ligands of the p-receptors, was in the 
late-90s. The precursor molecule of these peptides is still unknown. (Table 1.) 
Table 1. Mammalian endogenous opioid ligands 
Precursor Endogeneous Peptide Amino acid sequence1* 
Proopiomelanocortin ß-Endorphin YGGFMTSEKSQTPLVTLFKNA-
IIKNAYKKGE 
Proenkephalin [Met]-Enkephalin 
[Leu]-Enkephalin 
Metorphamide 
YGGFM 
YGGFL 
YGGFMRRV-NH2 
Prodynorphin Dynorphin A 
Dynorphin B 
a-Neoendorphin 
ß-Neoendorphin 
YGGFLRRIRPKLKWDNQ 
YGGFLRRQFKWT 
YGGFLRKYPK 
YGGFLRKYP 
Proendomorphin" Endomorphin-1 
Endomorphin-2 
YPWF-NH2 
YPFF-NH2 
presumed to exist, awaiting discovery 
busing a single letter code 
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Amongst many other biologically active compounds, frog skin contains opioid peptides: 
dermorphin [42] and the deltorphins [43,44], Dermorphin is a highly potent and selective p-
ligand, while the deltorphins, and especially deltorphin I and II, are selective 5-ligands with 
subnanomolar K; values in the binding assay. Deltorphin I and II are the most 5-selective 
natural opioids, with selectivity values of 21 000 and 3 450, respectively. 
New 6-peptide agonists were developed in order to improve the affinity and rather poor 
selectivity of the natural enkephalins. DADLE [45], DSLET [46] and DTLET [47] are potent 
analogues, but their 5-selectivity is relatively low. Therefore, conformational restriction [48-
51] of the enkephalin molecule was carried out by cyclization [49,50], resulting in a set of 
peptides, including DPDPE [52], which was both stable and highly selective for the 8-opioid 
receptor. Further chemical efforts have led to the replacement of the naturally occurring amino 
acids by conformationally constrained ones in the peptide sequence. Indeed, conformationally 
constrained DPDPE analogues were synthesized in order to enhance the selectivity of the 
parent peptide [53-55]. The development of a potent antagonist for any peptide hormone or 
neurotransmitter is of great importance for studies aimed at elucidating its physiological role. 
1.1.2.1. TIPP family 
The Tyr moiety is one of the key pharmacophores of opioid peptides. The discovery 
that opioid peptide analogues containing a Tic residue at position 2 are potent and highly 
selective 5-opioid antagonists léd to the new class of TIP(P) peptides in 1992 [56]. 
Unexpectedly, the result of a receptor binding study with [125I]TIPP indicated that substitution 
of an iodine atom at position 3' of Tyr in TIPP turned the 5-antagonist into a 5-agonist [57], 
The corresponding iodination of the Tyr residue in TIPP[*F], TICP and TIP did not result in 
agonism, suggesting that the astonishing conversion observed with TIPP may be due to an 
overall conformational effect rather than to a direct local effect of the iodine substitution. It is 
interesting that the substitution of a bromine or a chlorine at position 3' of Tyr in TIPP 
produced partial agonists with intrinsic efficacies [58], The Tyr(3'-F) analogue was again a 
pure 5-antagonist. Thus, systematic substitution of the halogen atoms, beginning with iodine 
and in the sequence of the periodic table, produced a progressive decrease in intrinsic activity 
and a concomitant increase in affinity at the 5-receptor. These findings indicate that the 
phenolic hydroxy group of Tyr contributes to the effective interaction with the opioid receptor, 
but is not an absolute requirement for opioid activity. 
Both TIPP and TIP are stable in an aqueous buffer solution of pH 7.7, but they have 
been found to be unstable in organic solvents and in a lipophilic membrane environment, due to 
spontaneous diketopiperazine formation and concomitant cleavage of the Tic2-Phe3 peptide 
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bond [59]. Pseudopeptide analogues containing a reduced peptide bond between the latter two 
amino acid residues have been prepared [60]. The resulting analogue T I P P ^ ] retained high 8-
opioid antagonist potency, showed further improved S-receptor affinity and displayed 
unprecedented 8-receptor selectivity. Similarly, TEP[T] was also a more potent and more 8-
selective antagonist than its parent TIP. Both TIPP[*F] and TIPfY] proved to be very stable 
against chemical and enzymatic degradation. Since TIPP and TIPP[*P] have very similar 
conformational properties, they served as parent peptides for the design of analogues. 
Systematic substitution at every position is useful for the determination of structure-activity 
relationships. 
Replacement of Tyr1 with Dmt in TIPP produced a very significant enhancement of the 
8-antagonist potency, but also a slight decrease in 8-receptor selectivity [58], Similarly, the 
Dmt1 analogue of the S-agonist DPDPE showed increased S-agonist potency and diminished 8-
selectivity [61]. These observations indicate that substitution of Dmt for Tyr1 in opioid 
peptides produces in general a substantial increase in 8-receptor affinity and an even more 
pronounced |x-receptor affinity enhancement. Interestingly, replacement of Tyr1 in TIPP by 
Hmt also increased the 8-receptor affinity, but had no effect on the p-receptor affinity [62], 
Structural modifications were performed at the Tic2 residue by replacement of the a -
carbon of Tic with a nitrogen. Such substitutions resulted in TIP and TIPP analogues in which 
the Tic residue was replaced by AzaTic [63], The tripeptide retained 8-antagonist affinity in the 
MVD assay, but was significantly less potent than the parent compound. The tetrapeptide 
turned out to be a quite potent p-agonist in the GPI assay, and a weak 8-agonist in the MVD 
assay, in contrast with TEPP, which has very weak p-receptor affinity. A molecular mechanics 
study of the modified tripeptide indicated that this peptide has conformational preferences 
similar to those of the parent TIP [64], but the heterocyclic ring in AzaTic is slightly different 
from that in Tic. The presence of the additional nitrogen in AzaTic creates the capacity for 
hydrogen-bond formation. Numerous substitutions with both natural and artificial amino acids 
have been performed at position 3 of the TIPP peptide sequence. The Trp3 analogues of both 
TIPP and TIP showed somewhat higher 8-antagonist potency and 8-selectivity than their 
parent peptides [65]. Elongation of the side-chain at position 3, achieved by substitution of 
Hfe, resulted in a new analogue of TIPP, which showed subnanomolar 8-antagonist potency 
and very high 8-selectivity [58], Substitution of a halogen atom in the para position of Phe3 led 
to compounds with slightly higher 8-antagonist potency and higher 8-selectivity than those of 
TEPP [66], Replacement at the same position with 2-Nal had little effect on the potency, but 
increased the 8-selectivity [58], The aromatic residues at positions 3 and 4 are not essential for 
high S-antagonism since they can be replaced by liophilic residues [65,67] or even omitted 
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[68], It has been shown that TEPP analogues in which the Phe3 residue has been replaced by 
Leu, lie or Nva have only slightly lower 5-antagonist potencies than that of the parent peptide, 
and similar 8-selectivity [65], The replacement of Phe3 in TEPP with a Cha residue resulted in 
an analogue TICP, with a 10-fold increased S-antagonist potency and a 4-fold improved 8-
selectivity [65], The corresponding pseudopeptide made from TICP was an even more potent 
and selective 8-antagonist with the adequate stability [65]. TICP[lP] is a stable S-antagonist 
with both extraordinary potency and extraordinary S-selectivity, being about 200 times more 8-
selective than naltrindole and 3 times more potent. 
Structural modifications have been made at the Phe4 residue through incorporation of 
various substituents in the para position of the aromatic ring in TEPP. Halogenation produced 
four compounds that all showed a slight increase in antagonist potency and S-selectivity. 
Phe(pN02) incorporation in TIPP resulted in a new compound which displayed higher 8-
receptor affinity and selectivity than those of TIPP [69], 
Determination of the hydrophobicity parameters by HPLC revealed that these modified 
peptides were significantly more lipophilic than TEPP [66], To enhance the lipophilicity of 
TEPP and TEPPfT], analogues containing various alkyl and aralkyl substituents were prepared 
[66]. The substituents were introduced on the N-terminal amino group of TIPP or on the 
secondary amino group of TIPPpF], Substitution of a n-hexyl group or of two ethyl groups on 
the N-terminal amino function of TIPP resulted in compounds with antagonist potency 
comparable to that of the TIPP peptide. In the receptor binding assays, all N-terminally 
substitued TIPP analogues showed high 8-receptor affinities and excellent 8-receptor 
selectivities. Introduction of a methyl substituent on the secondary amino group of the reduced 
peptide bond produced a compound with unchanged S-antagonist potency, high S-receptor 
affinity, and extraordinary 8-receptor selectivity. Analogous substitutions of TEPPf^] with an 
ethyl, n-hexyl, or phenethyl group led to compounds that displayed only slightly reduced 8-
antagonist potency as compared with TEPP[V] [66], These substitued pseudopeptides all had 
very weak affinity for ^.-receptors, and therefore still showed high receptor selectivity. 
Measurement of the hydrophobicity constants indicated that all alkyl- or aralkyl-substituted 
TIPP or TIPP[*F] analogues had a markedly increased lipophilic character. These various 
substitutions alone, or in combination can be expected to improve the ability of these 8-
antagonists to cross the BBB via passive diffusion. 
1.1.2.2. The Tyr-Tic pharmacophore and the effect of charge 
As mentioned above, deletion of the C-terminal Phe residue from TEPP resulted in a 
tripeptide analogue TIP, which was 4 times less potent S-antagonist than the parent 
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tetrapeptide and retained considerable 5 selectivity. Further, removal of the Phe residue in TIP 
furnished Tyr-Tic, which was the first opioid peptide without Phe that had 8-opioid selectivity 
and antagonist bioactivity [68], Substitution of the Tyr in Tyr-Tic by Dmt afforded the 
dipeptide antagonist Dmt-Tic, which had exceptionally high 5-affinity, ultraselectivity, and in 
vitro 5-antagonist activity [70] and acted systemically in vivo to reverse antinociception by a 8-
agonist [71]. Enhancement of the hydrophobic properties of Dmt-Tic through N-alkylation by 
methyl groups not only retained the high 5-affinity and 5-receptor selectivity, but also 
substantially enhanced the bioactivity [72,73]; other N-alkylating agents affected K¡8 and 
decreased the 8-selectivity [74], Further studies on the Dmt-Tic pharmacophore demonstrated, 
that replacement of the N-terminal amide through alkylation by piperidin-l-yl, pyrrolidin-l-yl 
or pyrrol-1-yl was detrimental for all bioactivity measurements on MVD [75], N-Alkylation by 
methyl groups to form secondary or tertiary amines was the only N-terminal substitution 
tolerated [74], These observations revealed that the hydrophobicity imparted by the 2'6'-
dimethylation of Tyr and N-alkylation was an important factor that influenced the interaction 
between the Dmt-Tic pharmacophore and the 5-opioid receptor ligand-binding domain in a 
tissue preparation. Amidation of TIP(P) [57,58,60], Tyr-Tic [68] and Dmt-Tic [70,72] allowed 
an exploration of the effect of charge on 8-receptor affinity. Suppression of the anionic 
function led to elevated (¿-receptor binding, a phenomenon also observed with the deltorphins 
[76,77], Dmt-Tic-X (X= -NH-NH2, -NH-CH3, -NH-tBu or -NH-l-adamantyl) had high 5-
affinities with variable (¿-affinities, to yield non-selective or weakly (¿-selective analogues. 
Similarly, the elimination of the negative charge in 5-agonists or antagonists by reduction of 
the acid to an alcohol also augmented binding to (¿-receptors [64], N,N-(Me)2Dmt-Tic-NH-l-
adamantane exhibited dual 5- and (¿-receptor affinities and potent 5-antagonism with (i-
agonism [75]. Moreover, C-terminal amidation with a change of configuration to D-Tic 
produced weakly (¿-selective compounds [58,70]. Other modification, such as the building-in 
of a methylene bridge between Ca of Tic and the carboxylate function to prevent 
diketopiperazine formation yielded H-Dmt-PHTic-OH, a biostable peptide with high 8-affinity 
and antagonism without (¿-bioactivity [75], The same chemical approach employing a 
methylene group between the amino group and Ca of Dmt was more detrimental [75]. 
Elimination of the C-terminal carboxyl function in the 5-antagonist H-Tyr-Tic-Atc-OH 
led to a compound H-Tyr-Tic-2-S-At, which turned out to be a full 5-agonist [78], Removal of 
the C-terminal carboxyl group in the 5-antagonist TIP also produced a compound with 5-
agonist properties, H-Tyr-Tic-NH-(CH2)2-Ph [79], Interestingly, shortening or lengthening of 
the C-terminal phenylethyl substituent by one methylene group converted this parent 
compound to a 8-antagonist. Analogues of H-Tyr-Tic-NH-(CH2)2-Ph containing a fluoro- or 
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chloro substituent in the para position of the aromatic ring of the C-terminal phenylethyl 
substituent also proved to be 5-antagonists, whereas an analogue of the same compound with a 
fluoro substituent at the orlho position of the phenyl ring retained 5-agonist potency [80], In 
comparison with the parent peptide, the analogue H-Tyr-Tic-NH-(CH2)2-Ph(o-Cl) exhibited 
increased 5-agonist potency in the MVD assay, and higher 5-receptor selectivity. Introduction 
of a second phenyl group on a (3-carbon of the phenylethyl moiety resulted in a compound, H-
Tyr-Tic-NH-CH2-CH-(Ph)2, which was 20 times more potent as a 5-agonist, with a 2-fold 
improved 5-selectivity. The corresponding analogue with a methylated N-terminal amino 
group, Tyr(NMe)-Tic-NH-CH2-CH-(Ph)2, displayed subnanomolar 5-agonist potency and still 
considerable 5-receptor selectivity. The most potent and selective agonist of this class of 
compounds was one of the isomers of H-Tyr-Tic-NH-CH2-CH(Ph)COOEt, which had high 5-
agonist potency and excellent 5-receptor selectivity. These results indicate that these ligands 
form a new class of potent and selective 5-opioid agonists and, because of their highly 
lipophilic character and low molecular weight, they are able to cross the BBB. Saturation of 
the aromatic ring of the phenylethyl moiety in H-Tyr-Tic-NH-(CH2)2-Ph again led to the 
compound H-Tyr-Tic-NH-(CH2)2-Ch with 5-antagonist properties [80], Replacement of the 
phenyl substituent with a Py moiety also brought about a conversion from 5-agonism to 5-
antagonism. Finally, reversal of the amide bond between the Tic residue and the phenylethyl 
substituent led to a compound, H-Tyr-Tia-CO-(CH2)2-Ph, that also turned out to be a 5-
antagonist [80], These results suggest that discriminative modifications at the C-terminus 
might result in opioids with new properties. 
1.1.2.3. Conformational analysis of the TIPP family 
The conformational behaviour of the tripeptide 5-agonist TIP was examined by 
theoretical conformational analysis based on molecular mechanics calculations and molecular 
dynamics simulations [81]. To determine possible receptor-bound conformations of TIP, a 
conformational comparison of its low-energy conformers with the structurally rigid non-
peptide 5-antagonist naltrindole was performed. On the basis of this study, two different 
models were considered initially, one based on a low-energy conformer identified through 
superposition of the centroids of the Tyr1 and Phe3 aromatic rings and the terminal amino 
group with the centroids of the corresponding aromatic rings and the nitrogen atom in 
naltrindole, and the other based on a low-energy conformer showing good spatial overlap of 
the centroids of the Tyr1 and Tic2 aromatic rings and the N-terminal amino group with the 
corresponding moieties in naltrindole. The latter model was selected as the more plausible one 
because of the demonstrated importance of the Tic2 aromatic ring for 5-antagonism [69], and 
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in view of the observation that the dipeptide H-Tyr-Tic-NH2 and the tripeptide H-Tyr-Tic-Ala-
OH were also 8-antagonists, albeit with much lower potency than that of TIP. This model is 
characterized by all-trans peptide bonds. 
An alternative model of the receptor-bound conformation of 5-opioid peptide 
antagonists containing the N-terminal dipeptide segment H-Tyr-Tic- has been devised [68]. 
This theory is also based on spatial overlap of the Tyr1 and Tic2 aromatic rings and N-terminal 
amino group with the corresponding aromatic rings and nitrogen group in the structurally rigid 
non-peptide 5-antagonist naltrindole. In contrast with the model with all-trans peptide bonds 
[81], the peptide bond between the Tyr1 and Tic2 residues in the latter model is cis [68], 
Furthermore, the Tyr1 aromatic ring in this model is tilted about 60° relative to the phenol ring 
in naltrindole. In a subsequent comparative assessment of these two models, a theoretical 
conformational analysis was performed on six 5-opioid peptide antagonists of this class: H-
Tyr-Tic-NH2, H-Tyr-Tic-Ala-OH, TIP, TEP[¥], TIPP and TIPPET] [82], Low-energy 
conformers consistent with both models were identified for all six compounds. The results of 
this study revealed that in all cases the conformers corresponding to the all-trans peptide bond 
model were lower in energy than the conformers corresponding to the model with the cis 
peptide bond. The conformers corresponding to the model with all-trans peptide bonds 
exhibited better coplanarity of their aromatic rings with the corresponding aromatic rings in 
naltrindole than did the conformers corresponding to the cis peptide bond-containing model. 
However, both models remained candidate structures for the receptor-bond conformation of 
the TIPP class. 
Both models differ from the crystal structure of TIPP, which is stabilized by numerous 
intermolecular hydrophobic contacts and does not represent the receptor-bond conformation 
[83], To distinguish between these two models, two pseudopeptides were prepared, H-
Tyr¥[CH2NH]Tic-Phe-Phe-OH and H-Tyr¥[CH2NH]MeTic-Phe-Phe-OH, in which the 
reduced peptide bond between the Tyr and Tic (MeTic) residues cannot assume the cis 
configuration for steric reasons [64]. Both compounds retained 5-opioid antagonist activity. 
For both of them, the results of a molecular mechanics study indicated a low-energy 
. conformation in which the torsion angle (©i) of the reduced peptide bond is 180° (trans 
configuration), in good agreement with the proposed model with all-trans peptide bonds. 
Furthermore, this conformational analysis revealed that neither of these peptides could exist in 
low-energy conformations in which ©i assumed a value of 0° (cis configuration). In the case of 
H-TyrvP[CH2NH]MeTic-Phe-Phe-OH, some conformations with the reduced peptide bond in 
the gauche(~) position (©i has a value of -60°) were identified. However, these conformers 
were higher in energy than the lowest-energy conformer and displayed no spatial overlap of the 
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three pharmacophore groups with the corresponding moieties in naltrindole. These results 
confirmed that the receptor-bound conformation of 5-peptide antagonists containing an N-
terminal H-Tyr-Tic dipeptide segment must have all-trans peptide bonding. The 
conformational behaviour of TIPP[*F] analogues with an alkyl substituent attached to the 
nitrogen of the reduced bond was also examined by theoretical conformational analysis [66]. 
At physiological pH, the tertiary amino group of the N-alkylated reduced peptide bond in these 
compounds may assume either the R or the S configuration. Molecular mechanics and 
molecular dynamics studies were performed on both diastereomers of H-Tyr-
TicvP[CH2N+HCH3]-Phe-Phe-OH and of H-Tyr-Tic^fCH^HCH^H^hJ-Phe-Phe-OH, and 
in both cases resulted in low-energy conformers that showed a good spatial overlap between 
the Tyr1 and Tic2 aromatic rings and the N-terminal amino group of the pseudopeptides with 
the corresponding aromatic rings and nitrogen atom of naltrindole. These low-energy 
conformers closely resembled the all-trans peptide bond model of the S-receptor-bond 
conformation of the parent peptide TIPPfV] [82], This finding provides an explanation for the 
fact that N-alkylation of the reduced bond in TIPP[XP] resulted in compounds that retained 
high 5-antagonist potency [66], Molecular dynamics simulations with the previous 
pseudopeptides containing the N-alkylated reduced peptide bond in protonated form revealed 
that the torsion angle ©2 around the CtySTHR bond predominantly assumes a value of -150° 
when the configuration is R, and a value of 150° in the case of the S configuration. These 
values are close to the value for the regular tram peptide bond. Fluctuations to ©2 values of -
60° and 60° (R and S configurations) were seen along the dynamics trajectory, but they were 
less frequent than for TEPP[V] in the protonated state [60], indicating that the non-alkylated 
reduced peptide bond is structurally more flexible than the N-alkylated reduced peptide bonds. 
The intramolecular distances between the Tyr1 and Tic2 aromatic rings in TIP(P) peptides were 
determined and the experiments led to the conclusion that a close hydrophobic interaction 
between the Tyr1 and Tic2 aromatic rings is prevented by the intercalation of the Phe3 aromatic 
ring in the tripeptide and of the Tic2-Phe3 peptide bond in the tetrapeptide. The Phe3 and Phe4 
aromatic rings are then quite exposed and could engage in receptor interactions, which might 
explain the higher antagonist potency of the tetrapeptides as compared with that of the 
tripeptides. It is clear that in such small peptides the amino acid side-chains exhibit 
considerable conformational flexibility, and establishment of an exact three-dimensional 
arrangement of the structural moieties constituting the 5-antagonist pharmacophore of TIP(P) 
remains a challenging problem. The use of (3-methylated amino acid to constrain the 
conformational mobility of the side-chain by biasing the population of the Xi torsion angle 
rotamers was pioneered by Hruby et al. [84,85], 
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1.1.2.4. Mixed ju-agonist / 8-antagonist members of the TIPP family 
Recent data on the knock-out of the p-opioid receptor in mice confirmed that the p-
receptor is primarily involved in the appearance of analgesia induced by morphine [28], 
Chronic co-administration of morphine and naltrindole has been reported to attenuate the 
development of tolerance and the severity of the precipitated withdrawal syndrome in mice 
[86]. In agreement with these results, rats chronically treated with TEPPfT] concurrently with 
chronic morphine administration over a 6-day period indicated no morphine tolerance and a 
significally reduced morphine dependence [87]. Recently, it was confirmed that 5-receptor 
occupation with naltrindole in rats chronically treated with morphine significantly attenuated 
the development of a physical dependence and antinociceptive tolerance, while not preventing 
the development of a tolerance to morphine-induced respiratory depression [88], Another 
interesting observation was that chronic morphine treatment resulted in an upregulation of the 
5-binding sites in rats [89]. The development of a morphine tolerance and dependence 
following 3 days of chronic morphine administration was blocked by an antisense 
oligodeoxynucleotide to the 8-opioid receptor [90], Finally, morphine was shown to retain its 
p-mediated analgesic activity in 5-receptor knock-out mice without producing analgesic 
tolerance upon chronic administration [91], These various observations clearly indicate that the 
S-opioid receptors play a key role in the development of morphine tolerance and dependence. 
These findings also suggest that 8-opioid antagonists may be useful therapeutic agents in 
analgesia in combination with p-agonists such as morphine. Alternatively, the development of a 
single opioid compound acting as an agonist at the p-receptor and as an antagonist at the 5-
receptor might be of benefit in the management of chronic pain. Such a mixed p-agonist/8-
antagonist would be an analgesic with a low propensity to produce analgesic tolerance and 
physical dependence. However, it should be noted that 5-receptor agonists act as non-
addicting analgesic drugs [92], which produce an antinociceptive response without the 
appearance of cross-tolerance to p-.or 8-opioid receptor agonists [93], and can lead to 
antinociception in the absence of the p-receptor [32], The first known compound with mixed 
p-agonist / 8-antagonist properties was the TIPP-NH2 [56], It was a moderately potent p-
agonist in the GPI assay and a potent 8-antagonist in the MVD assay. In the receptor binding 
assay, it was quite 6-receptor-selective and showed no affinity for K-receptors at 
concentrations up to 10 pM. Substitution of Dmt for Tyr1 in TIPP-NH2 resulted in a new 
compound, DIPP-NH2, which exhibited a major potency increase in the GPI assay and also, an 
enhancement in 5-antagonist activity in the MVD assay [94], The binding data revealed that 
this compound is still somewhat 5-receptor-selective. Reduction of the peptide bond between 
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Tic2 and Phe3 led to an analogue, DrPP[xP]-NH2 [95], which displayed a further increased p-
agonist property and retained very high 5-antagonist activity. This ligand showed 
subnanomolar binding affinities for both p- and 8-receptors and was the first example of a 
balanced mixed p-agonist / 5-antagonist. Dn>P[vF]-NH2 did not display 5-agonist activity in the 
MVD assay, even at very high concentrations, and was stable against chemical and enzymatic 
degradation. The conformational behaviour of the potent p-agonist / 5-antagonist DlPPf*?]-
NH2 was examined by theoretical conformational analysis based on molecular mechanics 
calculations. One low-energy conformer showed a good spatial overlap of its tyramine moiety 
and Phe3 aromatic ring with the tyramine moiety of Hat1 and the aromatic ring of Aic3 of the 
cyclic p-agonist peptide Hat-c[D-Orn-Aic-Glu] in a low-energy conformation. Another low-
energy conformer is almost identical with the proposed model of the receptor-bond 
conformation of the 5-antagonist TIPP [64], showing spatial overlap with the corresponding 
moieties of naltrindole, as discussed above. These findings might explain the mixed p-agonist / 
5-antagonist profile of DIPP[T/]-NH2. 
1.1.2.5. Other features of S-antagonists 
Moderately 5-selective alkaloid antagonists have found special applivations in clinical 
trials; for example, amelioration of the effect of alcoholism [96], autism [97] and Tourette's 
syndrome [98], In animal models, the 8-opiate antagonist naltrindole [99] inhibited the 
reinforcing properties of cocaine [100], moderated the behavioral effects of amphetamines 
[101], and brought about immunosuppression [102] suitable for organ transplantation. These 
transplantation effects were also seen when another non-peptide compound was used: 7-
(benzylspiroindanyl)naltrexone [103], 
1.2. Synthesis of amino acids [104] 
There is growing interest in the synthesis, pharmacology and conformational properties 
of non-proteinogenic amino acids. In the opioid peptide field, numerous conformationally 
constrained peptide analogues have been synthesized by the incorporation of unnatural amino 
acids. Racemic and enantiomerically pure substituted amino acids have been prepared by a 
number of different routes: 
• Strecker-Zelinsky synthesis 
• animation of a-halogen acids 
• amination via molecular rearrangement 
• condensation of an aldehyde with an active methylene group 
• Erlenmeyer condensation 
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• by condensation with N-substitued aminomalonic esters 
• oxidation of amino alcohols 
• Pictet-Spengler reaction [105] 
Since the starting material for these reactions is an aldehyde or a ketone, these 
procedures obviously result in racemic products and a suitable resolution procedure is required 
before peptide synthesis or, in the case of incorporation in racemic form, the resulting 
diastereomeric peptides can be separated by HPLC during purification. 
1.3. Separation of enantiomeric amino acids 
The synthesis of amino acids often leads to a racemic mixture. Enantiomers have 
identical chemical and physical properties in a symmetrical environment, but in a chiral 
environment such as the human body they act as two different molecules with quite different 
biological activities. Thus, separation of the enantiomers and determination of the enantiomeric 
purity are of high importance. Separation procedures can be divided into two classes, 
depending on the scale. 
1.3.1. Resolution of amino acids on a preparative scale 
Preferential crystallization by providing seed crystals of one antipode in a 
supersaturated solution of a racemate was employed in the resolution of a few amino acids. 
This method often fails to accomplish total separation of the enantiomers. 
Diastereomeric salts can be formed by the use of enantiomerically pure chiral ion-pair 
forming reagents. Due to the different solubilities of the resulting diastereomeric salts, they can 
be separated via differential crystallization from an appropriate solvent. Successful one-step 
resolution of a racemate presumes that the resolving agent forms a relatively tightly bound salt 
with at least one element of the racemate and that this salt is cleanly and quantitatively 
precipitable from that of the other isomer. Complete purification of each salt usually requires 
multiple crystallization and subsequent control of the enantiomeric purity. 
The advantage of using biological procedures to resolve amino acid racemates is that 
their action towards amino acids of unknown optical structure can be predicted. The drawback 
of these procedures is that they are not applicable when both antipodes are needed. Several N-
protected amino acids have been resolved by means of proteases, using bases such as aniline 
[106] or /7-toluidine [107], with papain as enzyme. Asymmetric enzymatic hydrolysis takes 
place in solution and analytical methods are available for monitoring the progress of the 
reaction. The method applies ¿-directed enzymes. The enzymes most extensively used for the 
resolution of a-amino acids are acylases and amidases. ¿-Antipodes of N-acetyl, chloroacetyl 
14 
or trifluoroacetyl amino acids as substrates, except Pro, are readily hydrolyzed by acylases or 
carboxypeptidases. 
1.3.2. Resolution of amino acids on an analytical scale 
Among the analytical methods applied for the separation of enantiomers of amino acids, 
chromatography, including GC, HPLC and TLC, is the most widely used. Polarimetry is also 
useable, but a knowledge of the specific rotation of the pure enantiomer is required. 
For direct separation, appropriate chiral selectors can be chiral ligands with metal ions 
[108], proteins [109], cyclodextrins [110], crown-ethers [111] and chiral counter ions [112]. 
These compounds, bound to a solid support, can also serve as a chiral stationary phase. This 
technique is a flexible and versatile one. Chiral derivatizing reagents applied for indirect 
enantiomeric resolution must fulfil many requirements. The reagent must be enantiomerically 
pure and provide a quantitative reaction without racemization or metabolism. It is 
advantageous to have both enantiomeric forms. The most widely used derivatizing agents for 
amino acids are Marfey's reagent [113] and the GITC reagent [114]. Lower limits of detection 
can be achieved by using fluorescent derivatizing agents such as orf/io-phthalaldehyde together 
with chiral thiols [115], 
Chiral TLC also provides a direct method for the resolution and analytical control of 
enantiomeric purity. This method is sensitive, and easy to carry out. Ligand exchange, ion 
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exchange (optically pure chiral selector) and molecular inclusion complexation (cellulose [116] 
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and cyclodextrin [117]) constitute the basis of these TLC separations. Quantification can be 
carried out by densitometry. The advantage of TLC over HPLC is that several analyses can be 
carried out on a single TLC plate while with GC or HPLC techniques all the analyses have to 
be performed sequentially. TLC additionally allows the easy control of synthetic processes. 
1.4. Solid-phase peptide synthesis 
Solid-phase peptide synthesis [118] is based on the sequential addition of a-amino or 
side-chain-protected amino acids to an insoluble polymeric support. The growing peptide chain 
is attached to the support via a linker through its C-terminus. The synthesis yields a peptide 
acid or amide, depending on the linker. Peptide synthesis can be carried out in a batchwise or 
continuous flow manner. Only the latter strategy is fully compatible with the continuous flow 
method. The acid-labile Boc or the base-labile Fmoc group is used for N-a-protection. After 
removal of the protecting group, the next protected amino acid is coupled by using either a 
coupling reagent or a preactivated protected amino acid derivative. Side-chain protecting 
groups are chosen so as to be cleaved simultaneously with detachment of the peptide from the 
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resin. In principle, Boc chemistry applies benzyl- and cyclohexyl-type protecting groups, while 
in Fmoc chemistry mainly fer/-butyl- and trityl-type protecting groups are used. Cleavage of 
the Boc protecting group is achieved with TFA, and that of the Fmoc protecting group with 
piperidine. DCM and DMF are the solvents primarily used for resin deprotection, coupling and 
washing. The most widely used quantitative test for the presence or absence of free amino 
groups is the Kaiser test [119]. It should be noted that some unprotected amino acids do not 
show the expected colour (Ser, Asn and Asp) or, being secondary amino acids do not yield a 
positive reaction (Pro and Tic). In these cases, other methods, such as picric acid monitoring 
[120], the TNBS test [121] and for Pro the chloranil test [122] are recommended. When the 
Fmoc continuous flow method is used, the progress of each deprotection can be followed by 
monitoring the release of the cleaved Fmoc group at 300-320 nm. 
Efficient peptide-bond formation requires chemical activation of the carboxyl 
component of N-a-protected amino acids. The activating group must be chosen carefully so as 
to achieve a very high coupling efficacy but to avoid side-reactions. There are four major types 
of these techniques: the carbodiimide, symmetrical anhydride, active ester and in situ activation 
methods. Carbodiimides are the most popular in situ activating agents in peptide synthesis. 
Reactions with DCC [123] are carried out at room temperature in DCM for up to 12 hours. 
The principal limitation to the use of carbodiimides is the dehydration of Asn or Gin. To 
prevent this side-reaction, HOBt should be used, which also has an accelerating effect on the 
coupling [124], An important drawback to the use of DCC is the DCM-insoluble DCU during 
activation. Other carbodiimides used in SPPS, such as DLPCDI [125], form urea, which is 
more soluble in DCM than DCU. In situ activating reagents have recently become very popular 
because of the fast reactions and the lack of undesired side-reactions. They are mainly 
phosphonium and uronium salts and react in the presence of a tertiary base. The most 
important active ester is the HOBt ester [126], This compound is formed in situ when HOBt, 
BOP [127], PyBOP [128], TBTU [129] or HBTU [130] is used, and is not isolated. BOP 
should be handled with care as the by-product formed during the activation is carcinogenic. 
Pentafluorophenyl esters [131] are also efficient, but react somewhat more slowly. PyBroP 
[132] allows fast and enantiomerization-free couplings, providing a significant improvement 
over existing reagents. Symmetrical anhydrides are formed in situ when two equivalents of the 
N-protected amino acid and one equivalent of DCC are used. This method is quite wasteful, 
and the anhydrides have to be prepared freshly prior to use. 
Final cleavage of the peptidyl-resin and side-chain deprotection is achieved through the 
application of HF or TFMSA for Boc chemistry and TFA for Fmoc chemistry. Standard 
conditions for HF cleavage are 0-5 °C for a period of 30-60 min. The scavenger most widely 
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used to avoid side-reactions is anisole in combination with dimethyl sulfide. /?-Thiocresol in 
combination with the previous scavenger can prevent the alkylation of Met and Cys residues. 
Unfortunately, HF is highly toxic and reactive, and special Teflon apparatus is required. As an 
alternative to HF, other strong acids, such as TFMSA, or for amide C-terminus peptides, 30% 
HBr/AcOH, can be applied in normal laboratory glassware. In Fmoc chemistry, cleavage of the 
peptide-resin bond and simultaneous deprotection is carried out with TFA. Met, Cys and Trp 
are extremely susceptible to alkylation by cations produced during the cleavage process. If 
scavengers such as EDT or thioanisole are added to the cleavage mixture, these side-reactions 
can largely be suppressed. A shorter process can be achieved if HBF4 or trimethylsilylbromide 
is used to remove less acid-sensitive protecting groups as an alternative to TFA cleavage. 
In most cases, the post-cleavage work-up consists in precipitation of the crude peptide 
from the cleavage mixture with diethyl ether. The peptide is then washed with diethyl ether to 
remove scavengers and is lyophilized from AcOH or from buffer solutions. In order to achieve 
high peptide purity, purification by RP-HPLC is necessary. Purified peptides can be stored as 
lyophilizates at -20 °C. 
1.5. Tritium labelling of peptides 
Tritium occurs naturally in the environment. Reactions between cosmic radiation and 
gases in the upper atmosphere produce most of the world's natural tritium: 
Tritium is a pure P-emitter with an Em* of 18 keV. It has a half-life of 12.4 years. A P particle 
is identical with an electron. One milliatom of tritium represents a radioactivity of 28.6 Ci 
(1.080 TBq). 
In the opioid field, tritiated peptide ligands have proved to be essential for the 
performance of binding experiments, autoradiographic localization and distribution studies of 
the receptors, and to confirm that the cloned receptors are identical with those characterised in 
native tissues. Tritium incorporation can involve non-selective labelling, such as isotope 
exchange reactions [133], or selective labelling, such as the chemical or enzymatic synthesis of 
peptides from labelled amino acids, derivatization of the neuropeptides with [3H]methyl iodide 
[134] or reductive methylation with tritiated metal hydrides [135] and the synthesis of 
[3H]neuropeptides by using precursor peptides (Figure 1). The precursor can be obtained by 
peptide synthesis using amino acid derivatives containing halogens, or double or triple bonds. 
Tritium labelling can be performed on precursor peptides gained by direct synthesis or by post-
synthetic modifications [136,137], 
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Tyr and His residues can be iodinated with I2. For this purpose, I2 can be used directly 
in a MeOH solution, formed from I" by oxidation with chloramine-T or iodogen; by 
electrolysis, etc. Mono- and diiodinated analogues can be prepared, depending on the 
iodine/substrate ratio, the temperature and the reaction time, but the reaction mixture usually 
contains a mixture of iodinated and non-iodinated peptides. The diiodinated analogue can be 
separated by HPLC purification. The resulting substitutions are situated at positions 3' and 5' 
in the aromatic rings in Tyr or at positions 2' and 4' in the His residue. Peptides containing 
Trp, Met or Cys may be damaged in the case of direct halogenation. To prevent such 
obstacles, fragment condensation is an appropriate approach [138], Tritiated neuropeptides can 
also be prepared by using precursor peptides obtained by peptide synthesis. Boc and Fmoc 
chemistry can equally be used, but in the event of double bonds Fmoc chemistry is preferred. 
The most popular amino acids are Dit or 3',5'-dibromotyrosine. 2',6'-Dibromotyrosine can be 
used to place the labels in more stable positions [139], The use ofp-iodophenylalanine results 
in lower specific activity in the tritiated peptide, but the label itself will be more stable [140], 
Other frequently used precursor amino acids are 3,4-dehydroproline [141], 4,5-dehydroleucine 
[142] and propargyl- [143] or allylglycine. 
Pd0/BaS04 is the most widely applied catalyst for the tritiation of halogen-containing 
peptides [144], but Pd/C and carrier-free Pd catalyst have also been applied for the labelling of 
opioid peptides [145,146], 
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Figure 1. Reaction routes rot the synthesis of tritiated peptides 
18 
2. AIMS AND SCOPE 
The development of antagonists, which selectively block the action of the agonist, 
presumably by binding to the receptors, has been of spectacular help in elucidating the function 
of those ligands for which antagonists have been developed. We set out to synthesize several 
peptides from the TIPP peptide family in order to study their biological properties. The 
systematic substitution of every position with 3-methylated amino acids in the 5-antagonist 
TIPP and the mixed p-agonist / 5-antagonist TIPP-NH2 is useful for the determination of 
structure-activity relationships. In the case of 5-antagonist TIPP, we wished to develop new, 
highly potent and selective 5-opioid antagonist peptide ligands. Substitution of Dmt for Tyr1 in 
opioid peptides in general produces a substantial increase in 5-receptor affinity and the 
exchange improves the ability of these 5-antagonists to cross the BBB. Accordingly we set out 
to devise a new method for synthesis of the optically pure L-Dmt, and to use this amino acid in 
our new, Dmt-substitued analogues. In the case of the mixed p-agonist / 5-antagonist TIPP-
NH2, it was hoped that the P-methyl substitution might result in more balanced p- and 5-
affinities, thereby leading to new analgesics with a diminished propensity to produce tolerance 
and dependence. 
Tritium-labelled biologically active peptides are valuable tools for the biological 
characterization of receptors and binding sites. The metabolic pathway of tritium-labelled 
compounds is also easily traceable, facilitating the study of biological properties. After 
biological characterization of our new, structure-activity-tested analogues we choose some of 
the promising ligands and prepare them in tritium-labelled form. We decided to synthesize 
labelled forms of some other 5-antagonists reported to be the best in their field too, because 
data from indirect membrane receptor binding assays sometimes resulted in ambiguous 
findings. To determine the correct values, we synthesize two new, highly potent and selective 
ligands with sufficient stability, TICPPF] and N,N-(Me)2Dmt-Tic-OH in radiolabeled form 
from their corresponding halogen-containing precursor peptides.The tritiated ligands of high 
specific radioactivity could help to decide the question and might be useful tools for the 
biological characterization of other new 5-antagonists. 
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3. MATERIALS AND METHODS 
Protected and unprotected amino acids (except (3-methyl amino acids and Dmt), resins, 
coupling reagents, GITC and Carboxypeptidase A, Type II from bovine pancreas (5 000 U / 
5.1 cm3) were purchased from Sigma-Aldrich Ltd., from Bachem Feinchemicalien AG or from 
Fluka. All other reagents and solvents were of analytical or reagent grade and were used 
without further purification. 
TLC analyses were performed on precoated plates (Merck, Kieselgel 60 F254) using the 
following solvent systems: ( 1 ) hexane-ethyl acetate (9:1) 
(2) hexane-ethyl acetate (1:1) 
(3) methanol-chloroform-ammonium hydroxide (5:5:1) 
(4) n-butanol-acetic acid-water (4:1:1) 
(5) acetonitrile-methanol-water (4:1:1) 
(6) n-butanol-acetic acid-pyridine-water (38:6:24:20) 
(7) ethyl acetate-acetic acid-pyridine-water (60:6:20:11) 
UV light, I2 and ninhydrin were applied to detect the compounds. Radioactive traces were 
checked with a Berthold Radichromatogram Tracemaster. 
RP-HPLC analyses of the synthesis of Dmt were performed on a Spectra-Physics 
SpectraSystem P 4000, UV 2000 and DataJet Integrator. The column was a Vydac 218TP54. 
The detection was at 275 nm. 
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Other analyses were carried out on a Merck-Hitachi chromatograph, applying a Vydac 
218TP54 column for analytical and a Vydac 218TP1010 column for preparative purposes. UV 
detection at 215 nm was applied for detection. Final products were obtained as lyophilizates. 
For radiochemical purification, we used a Jasco PU 980 HPLC equipped with Merck 50943 
LiChroCart 125-4 LiChrospher 100 RP-18 or Vydac 218TP54 columns. Detection was 
performed with a Jasco UV-975 detector at 215 nm and a Packard Flow-one/p A-500 
radiodetector. Radioactivity was counted with a Searle-Delta-300 liquid scintillation counter in 
a toluene-Triton X-100 scintillation cocktail. 
Analytical characterizations were performed by using a linear gradient of ACN-0.1% 
TFA (eluent B) from 0 to 80% over 30 min. Water-0.1% TFA was eluent A 
H-[3H]Dmt-Tic-OH was purified to homogeneity with a gradient programme: 0 min, 
15% B; 10 min, 20% B; 15 min, 32% B and 25 min, 50% B. For N,N(Me2)-[3H]Dmt-Tic-OH, 
the following programme was applied: 0 min, 20% B; 10 min, 30% B; 15 min, 40% B. 
[3H]TICP[*P] and [3H]-N(Me)Phe3TIPP[vP] were assessed by using a linear gradient 
from 25% to 50% ACN in 0.1% TFA over 30 min. 
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[3H]-(£;-I/ireo-Phe3-TIPP, [3H]-(Z);-^reo-Phe3-TIPP and [3H]-(L>/Areo-Phe3-DIPP 
were purified by using a linear gradient from 25 to 60% ACN in 0.1% TFA over 30 min. 
The molar masses of the peptides were determined by electrospray ionization mass 
spectrometry (Finnigan TSQ 7000) and by fast atom bombardment ionization mass 
spectrometry (AEI/902S) using xenon gas. The GC-MS was equipped with a Chirasil-Val 50 
m column. 
!H NMR measurements were performed on a Bruker AC 250-P 250 MHz 
spectrometer. 
Melting points were determined on a Buchi 510 apparatus and were uncorrected. 
The catalyst for tritiation, Pd0/BaS04 (10% Pd), was from Merck. A Pd/C catalyst 
(10% type 90, Johnson Matthey) was applied for the hydrogenation of methyl butenoate. 
Synthesis of L-2 ',6 '-dimethyltyrosine 
0-Carbethoxy-3,5-dimethylphenol 
60 cm3 of pyridine was added to a solution of 74 g (0.6 mol) of 3,5-dimethylphenol in 
500 cm3 of benzene, and 75 cm3 (0.74 mol) of ethyl chloroformate was added dropwise under 
stirring. The reaction mixture was stirred for 1 hour at RT. The reaction mixture was filtered 
and the filtrate was evaporated to an oily residue. The oil was distilled under reduced pressure 
in a one-piece distillation flask equipped with a Vigreux column. The fraction with b.p. 62-64 
°C / 13.3 Pa was collected to give 76.7 g (65.2%) of 0-carbethoxy-3,5-dimethylphenol. TLC 
was performed to follow the reaction. The Rf(l) values of 3,5-dimethylphenol and the product 
were 0.28 and 0.58, respectively. 
0-Carbethoxy-3,5-dimethyl-4-chloromethylphenol 
Anhydrous hydrogen chloride was introduced at a flow rate of 70-80 cm3/min into a 
stirred mixture of 12.8 g (66 mmol) of 0-carbethoxy-3,5-dimethylphenol, 51 cm3 of 37% 
aqueous formaldehyde (0.678 mol) and 25 cm3 of 32% hydrochloric acid and the temperature 
was maintained at 40 °C for 6.5 hours. The product was formed as a white solid. The 
crystalline product was filtered off, washed twice with water, and then extracted with ethyl 
acetate. The organic solution was dried over anhydrous sodium sulfate and evaporated in 
vacuum. The procedure resulted in 15.2 g of solid material (95%). This solid was distilled 
under reduced pressure (0.66 Pa and at 116-118 °C) in a one-piece flask equipped with a 
Vigreux column, to give 6.84 g (45%) of a mixture of 0-carbethoxy-3,5-dimethyl-2-
chloromethylphenol and 0-carbethoxy-3,5-dimethyl-4-chloromethylphenol. The ratio of the 
isomers was investigated by GC-MS: 11.9% of 0-carbethoxy-3,5-dimethyl-2-
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chloromethylphenol, 85.9% of 0-carbethoxy-3,5-dimethyl-4-chloromethylphenol and 2.2% 
impurity was found. TLC was applied and the Rf(l) values of O-carbethoxy-3,5-
dimethylphenol and the mixture of 0-carbethoxy-3,5-dimethyl-2-chloromethylphenol and O-
carbethoxy-3,5-dimethyl-4-chloromethylphenol proved to be 0.58 and 0.43, respectively. 
Diethyl acetamido-(2,6-dimethyl-4-hydroxybenzyl)malonate 
Sodium ethoxide was prepared by adding 1.1 g of Na (47.6 mmol) to 90 cm3 of abs. 
ethanol. 10.2 g of diethyl acetamidomalonate (47 mmol) and 9.4 g of a mixture of O-car-
bethoxy-3,5-dimethyl-2-chloromethylphenol and 0-carbethoxy-3,5-dimethyl-4-chloromethyl-
phenol (39 mmol) were added to this solution. The mixture was refluxed for 2 hours, cooled 
and filtered; filtrate was then evaporated to give a foam. This was dissolved in about 120 cm3 
of ethyl acetate and washed twice with about 60 cm3 of water. When the organic phase was 
dried over anhydrous sodium sulfate and evaporated again, it started to crystallize. The 
collected crystals were recrystallized from benzene. The procedure resulted in 7.2 g of diethyl 
acetamido-(2,6-dimethyl-4-hydroxybenzyl)malonate. TLC was performed and the Rf(2) values 
of the starting compound and the product were found to be 0.9 and 0.33, respectively. The 
melting point was 154-155 °C. To verify the purity and to determine the ratio of ortho and 
para isomers, RP-HPLC analysis was performed; the tR value of diethyl acetamido-(2,6-
dimethyl-4-hydroxybenzyl)malonate was 18.8 min, while that of diethyl acetamido-(4,6-
dimethyl-2-hydroxybenzyl)maIonate was 18.5 min. 
(D,L)-N-Acetyl-2', 6 '-dimethyltyrosine 
20.4 g of diethyl acetamido-(2,6-dimethyl-4-hydroxybenzyl)malonate (58 mmol) was 
hydrolysed by refluxing in 75 cm3 of 2 M sodium hydroxide solution for 40 min. After cooling, 
3 M HC1 solution was added dropwise to the mixture under stirring until pH = 2 was attained. 
The separated acetylamino acid was filtered off, and washed with cold acidified water (pH = 2) 
and acetonitrile. 12.7 g of (Z?,Z)-N-acetyl-2,6-dimethyltyrosine (87%) was formed. HPLC gave 
tR = 11.5 min. The Rf(3) value was 0.83. 
(D,L)-2 ',6'-Dimethyltyrosine 
10 g of (£),L)-N-acetyl-2 ',6 -dimethyltyrosine (40 mmol) was refluxed with 80 cm3 of 6 
M HC1 for 6.5 hours. The solution was concentrated in vacuum to give (D,L)-2,6-
dimethyltyrosine hydrochloride. It was then dissolved in about 50 cm3 of warm water, and the 
solution was neutralized to pH = 6.5 with aqueous sodium carbonate, and cooled. The crystals 
of Dmt were collected and washed with acetone or diethyl ether to give 6.05 g of product 
(72.6%). HPLC gave tR = 9.6 min. MS (ESI): 210 (MET). The m.p. was 230-231 °C, with 
decomposition. 
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(D,L)-N-Trifluoroacetyl-2 ',6'-dimethy ¡tyrosine 
3 g of Dmt (12 mmol) was dissolved in 24 cm3 of trifluoroacetic acid, the flask was 
placed in an ice-bath, and 7 cm3 of trifluoroacetic anhydride was added dropwise. The mixture 
was stirred and after stirring for 15 min, the temperature was allowed to return to RT. The 
reaction time was 3 hours. After evaporation, the yield was 4.3 g (98%). MS (ESI): 306 
(MH*). HPLC gave tR = 16 min. 
L-26 '-Dimethyltyrosine 
(D,Z,)-N-Trifluoroacetyl-2',6-dimethyltyrosine (4.3 g) was suspended in 45 cm3 of 0.1 
M K2HP04 buffer (pH = 7.5), the pH was adjusted to 6.5-7.5 with 2 M NaOH, 120 pi of a 
suspension of Carboxypeptidase A, Type II was added and the reaction mixture was shaken for 
6 hours at 37 °C. From time to time, the pH was adjusted to 6.5-7.5. The solution was then 
evaporated, the solid residue was dissolved in water, the pH was adjusted to 2-3 with dilute 
HC1 and the solution was extracted 3 times with EtOAc. The aqueous phase was next 
neutralized with 2 M NaOH and evaporated to about half volume, and the crystals were 
filtered off. 0.98 g (65.3% for the resolution) product was obtained. *H NMR (DMSO-de/10% 
D20): 5 2.16 (6H,s,Ar-CH3), 2.63-2.72 (lH,dd,Hp J = 8.3 and 14.6 Hz), 3-3.12 (lH,dd,Hp J = 
14.6 and 6.3 Hz), 3.24-3.29 (lH.dd.H11 J = 8.3 and 6.3 Hz), 6.38 (2H,s,Ar-H). HPLC gave tR 
= 9.6 min. MS (ESI): 210 (MH+). M.p. 230-231 °C with decomposition. To determine the 
enantiomer excess, GC-MS assay was performed after derivatization; this gave a value of 91 
%. 
Synthesis of erythro-fi-methyltyrosine 
2-Phenyl-4-[a-E/Z-p-methoxyphenylethylidene]-5(4H)-oxazolone 
A mixture of 15 g hippuric acid (0.08 mol) and 23 cm3 of acetic anhydride was cooled 
to about 10 °C and 9 cm3 of H2S04 was added dropwise under stirring. To this solution, 12.5 g 
of methoxyacetophenone (0.09 mol) was introduced and the mixture was allowed to reach RT. 
After heating at 60 °C for 15 min, the mixture was left under stirring overnight at RT. The 
resulting brown oil was poured into 150 cm3 of ice-cold water, when the product precipitated. 
It was washed 3 times with cold water and 100 cm3 of hot water was added to the solid during 
stirring. The residue was filtered off, dried over P2Os, and crystallized from 350 cm3 of hot 
ethanol to give 20.4 g (83%) of product {E/Z 70:30). Repeated crystallization from ethanol 
resulted in a mixture of oxazolone {E/Z 98:2) with a yield of 68%. *H NMR (CDCI3): 5 2.64 
(3H,S,CH3), 3.85 (3H,S,OCH3), 6.93 (2H,d,arom. J = 8.4 Hz), 7.5 (5H,arom), 8.08 
(2H,d,arom. J = 8.4 Hz). MS (FAB): 294 (MH*). M.p. 123-127 °C, TLC: R{(2) = 0.77. 
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Isolation of 2-phenyl-4-[a-Z-p-methoxyphenylethylidene]-5(4H)-oxazolone 
A solution of 0.3 g of the oxazolone (E/Z 70:30) in 15 cm3 of pyridine was stirred for 
10 min at RT. The mixture was poured into 0.24 M ice-cold HC1 solution. The precipitated 
material was quickly filtered off, the residue was dissolved in 300 cm3 of hot ethanol and the 
dicalite was filtered off. On addition of extra water to the solution, the oxazolone (E/Z 4:96) 
crystallized with a yield of 73% (0.22 g). NMR (CDC13): 5 2.77 (3H,s,CH3), 3.877 
(3H,S,OCH3), 6.98 (2H,d,arom. J = 8.2 Hz), 7.5 (5H,arom), 8.07 (2H,d,arom. J = 8.2 Hz). 
MS (FAB): 294 (MH*). M.p. 95-98 °C. TLC: R{(2) = 0.77. 
E-2-Benzjoylamino-3-p-methoxyphenyl-2-butenoic acid methyl ester 
To a solution of 125 mg of Na (5 .43 mmol) in 50 cm3 of anhydrous methanol, 5 g of 
oxazolone (E/Z 98:2) (17.1 mmol) was added cautiously. This mixture was shaken at RT for 2 
hours. The precipitated solid was filtered off. and washed with methanol. The filtrate was 
neutralized with cc. HC1 solution, and further precipitation started. The product was collected 
by filtration again. The combined solids were crystallized from ethanol/water and a yield of 
4.77 g (86%) of the E isomer was obtained. *H NMR (CDC13): 5 2.16 (3H,s,CH3), 3.5 
(3H,S,OCH 3) , 3 .87 (3H,S,COOCH 3) , 6.86 (2H,d,arom. J = 8.7 Hz) , 7 .16 (2H,d,arom. J = 8.7 
Hz), 7 .35 (3H,arom.), 7 ,86 (2H,arom ). MS (FAB): 326 (MHT). M.p. 147-148 °C, TLC: R<2) 
= 0.33. 
Z-2-Benzoylamino-3-p-methoxyphenyl-2-butenoic acid methyl ester 
The synthesis started from Z-oxazolone (E/Z 4:96) and the procedure was the same as 
above. *H N M R (CDC13): 5. 2.29 (3H,s,CH3), 3.5 (3H,s ,QCH 3 ) , 3.8 (3H,S,COOCH 3 ) , 6 .86 
(2H,d,arom. J = 8.7 Hz), 7.16 (2H,d,arom. J .= 8.7 Hz), 7.35 (3H,arom), 7.86 (2H,arom ). 
M.p. 138-140 °C, M S and T L C RF(2) identical with that of the E isomer. 
erythro-N-Benzoyl-fi-methyl-p-methoxyphenylalanine methyl ester 
A mixture of 4.73 g of the E isomer of the foregoing butenoic acid methyl ester (14.5 
mmol) in 190 cm3 of methanol and 0.4 g of Pd/C catalyst'was hydrogenated for 4 days at RT 
at a pressure of 345 kPa in a Parr hydrogenator. The catalyst was then filtered off over a layer 
of celite, and the filtrate was evaporated in vacuum. The resulting yellow oil was dissolved in 
hot ethanol and crystallization started after the addition of water. The yield was 3.77 g (76%). 
*H NMR (CDC13). 8 1.38 (3H,d ,CH 3 J = 7.2 Hz), 3.46 (lH,m,Hp), 3.72 (3H,s ,COOCH 3 ) , 3.78 
(3H,S,OCH3), 5 (lH.dd.H" J = 8.1 and 5.2 Hz), 6.28 (lH,d,NH J = 8.1 Hz), 6.86 (2H,d,arom. 
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J = 8.6 Hz), 7.12 (2H,d,arom. J = 8.6 Hz), 7.45 (3H,arom.), 7.67 (2H,d,arom. J = 8.7 Hz). MS 
(FAB): 328 (MlT). M.p. 80-83 °C, TLC: Rf(2) = 0.42. 
threo-N-Benzoyl-fi-methyl-p-methoxyphenylalanine methyl ester 
The synthesis started from butenoic acid methyl ester (E/Z 20:80) and the 
hydrogenation was the same as above (the spectrum contained additional signals of the erythro 
isomer). 'H NMR (CDC13): 5 1.43 (3H,d,CH3 J = 7.3 Hz), 3.46 (lH,m,Hp), 3.72 
(3H,s,COOCH3), 3.78 (3H,s,OCH3), 4.96 (lH,d,H° J = 5.2 Hz), 6.54 (lH,d,NH J = 8.2 Hz), 
6.86 (2H,d,arom. J = 8.6 Hz), 7.12 (2H,d,arom. J = 8.6 Hz), 7.45 (3H,arom.), 7.67 
(2H,d,arom. J = 8.7 Hz). M.p. 125-128 °C. MS and TLC Rf(2) identical with that of the 
erythro isomer. 
erythro-fi-Methy¡tyrosine 
To a solution of 5.2 cm3 of 48% aqueous HBr and 10.4 cm3 of acetic acid, 1 g (3 
mmol) of e/y//iro-N-benzoyl-P-methyl-/?-methoxyphenylalanine methyl ester was added. The 
mixture was refluxed for 24 hours and evaporated. The resulting oil was dissolved in water and 
evaporated again. After repeated addition of 5 cm3 of water, the flask was placed into a 
refrigerator. The precipitated crystals were filtered off and the filtrate was extracted with ethyl 
acetate. The aqueous phase was adjusted to pH = 6 with NH4OH, and erythro-$-
methyltyrosine precipitated. The crystals were filtered off and recrystallized from hot water; a 
yield of 361 mg (58%) was obtained. *H NMR (D20/TFA): 5 0.94 (3H,d,CH3 J = 7.2 Hz), 
3.07 (lH,m,Hp), 3.65 (lH.d.H0 J = 7.2 Hz), 6.43 (2H,d,arom. J = 8.6 Hz), 6.75 (2H,d,arom. J 
= 8.6 Hz), 13.6 (lH,s,COOH). MS (FAB): 196 (MET). M.p. 228-231 °C, TLC: Rf(4) = was 
0.47. 
threo-fk-Methy¡tyrosine 
//ireo-N-Benzoyl-P-methyl-p-methoxyphenylalanine methyl ester was hydrolysed in 
48% aqueous HBr and acetic acid as above. Any erythro isomer was removed by 
chromatography on a Lobar (Merck) LiChroprep RP8 (40-63) column, using 1% aqueous 
methanol as eluent. *H NMR (DzO/TFA): 5 1.31 (3H,d,CH3 J = 7 Hz), 3.37 (lH,m,Hp), 4.11 
(lH,d,Ha J = 7.2 Hz), 6.43 (2H,d,arom. J = 8.6 Hz), 6.81 (2H,d,arom. J = 8.6 Hz), 13.6 
(lH,s,COOH). MS (FAB): 196 (MFC). M.p. 228-231 °C, TLC: R<4) = 0.47. 
N-tert-Butyloxycarbonylamino acids [147] 
Boc-AAs were prepared from the given AA in dioxane-water 2:1 at pH = 10 with 1.1 
equivalents of Boc20. After stirring for 3 hours, an additional portion of Boc20 (0.3 
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equivalents) was added and stirring was continued overnight at RT. After extraction with 
EtOAc, the resulting brownish oil was dissolved in EtOAc and precipitated with petroleum 
ether. 
Solid-phase peptide syntheses 
These were performed by the manual solid-phase technique, using 4-
methylbenzhydrylamine resin for peptide amides or Merrifield resin for peptide acids. Coupling 
was performed by shaking the resin with two equivalents of Boc-amino acid, HOBt and DCC 
for 1-1.5 hours. The resin was then washed with DCM, EtOH and DCM again (3 times each). 
Coupling was monitored with the Kaiser test. Boc-deprotection was carried out by treating the 
peptidyl resin with 50% TFA/DCM containing 2% of anisole (5+20 min), and the resin was 
washed then with DCM, (3 times) neutralized with 10% DEEA/DCM (2 times) and washed 
with DCM again (3 times), threo-P-MePhe was incorporated as racemate into the TEPP 
analogue peptide sequences. After RP-HPLC purification, two diastereomeric peptides were 
obtained. After acid hydrolysis, [142] GITC derivatizations were performed and the resulting 
mixtures were compared with standards. Side-chain protection was with dichlorobenzyl for 
Tyr. Simultaneous side-chain deprotection and cleavage from the resin were accomplished by 
treatment with HF and anisole as scavenger (1 cm3 of anisole and ~10 cm3 of HF/g peptide 
resin) at 0 °C for 1 hour. After evaporation of the HF, the peptide resin mixture was washed 
with diethyl ether and the peptide was extracted with glacial acetic acid and lyophilized. 
Postsynthetic modifications 
Iodination of peptides wase performed as follows: The peptide was dissolved in 
ACN/water (1:1), and Nal (in ACN/water solution) and chloramine-T (in ACN/water solution) 
were added. After stirring at RT, the product, which contained a mixture of iodinated and 
diiodinated peptides, was separated by HPLC. Purified precursor peptides were characterized 
by HPLC and MS analyses. 
Acid hydrolysis was performed as follows: To 1 mg of peptide, 1 cm3 of 6 M HC1 was 
added, and the mixture was incubated at 110 °C for 2 days in a sealed ampoule. The 
hydrolysate was analysed by RP-HPLC after GITC derivatization. 
GITC derivatization was performed as follows: Equal volumes of amino acid solution 
(1 mg/cm3, dissolved in 0.4% TEA/ACN:water (1:1)) and 0.2% GITC solution in acetonitrile 
were mixed. The mixture was allowed to stand at RT for 60-90 min, and was then injected 
directly into the HPLC. GITC-AA has an absorption maximum at 250 nm. 
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Tritium labelling of peptides 
This was carried out in an in-house designed vacuum apparatus [148] in a fume 
cupboard. The purified precursor peptide was dissolved in DMF and the catalyst was 
suspended in the solution. The reaction vessel was then connected to the tritiation manifold 
and cooled with liquid nitrogen, and the air was removed by vacuum. Tritium gas was liberated 
from uranium tritide by heating above 300 °C, and it was expanded into the reaction vessel. 
The reaction mixture was agitated with a magnetic stirrer at RT. The reaction was terminated 
by freezing the solution and adsorbing the remaining tritium on pyrophoric uranium in another 
reservoir. The catalyst was removed by filtration through Whatman GF/C filters, and was 
washed several times with ethanol. Labile tritium was removed by repeated evaporation of an 
ethanol-water (1:1) solution. In most cases, further TLC or HPLC purification was necessary. 
The purified labelled peptide was dissolved in ethanol and stored under liquid nitrogen. 
The specific activities of the labelled peptides were determined by dividing the 
measured activity by the amount of purified peptide. UV detection was performed on a 
Shimadzu-160 spectrophotometer. The quantity of the purified labelled material was 
determined from its UV absorption, or by HPLC, using a calibration curve. 
Receptor binding assays were performed with 50 mM Tris-HCl buffer (pH 7.4) in a 
final volume of 1 cm3 and at a protein concentration of 0.3-0.5 mg/cm3. Incubation was started 
by addition of the rat brain membrane suspension, and terminated by rapid vacuum filtration 
through Whatman GF/C filters. The radioactivity was measured by LSC in a toluene-based 
scintillation cocktail. Non-specific binding was determined in the presence of 10 pM non-
labelled naloxone. Specific binding is the difference between the total binding and the non-
specific binding. Scatchard plots were used for the analysis of radioligand binding saturation 
curves. The displacement curves of [3H]TICP[*F] were analyzed with the LIGAND program 
[149], using a non-linear least squares algorithm. Ki values were determined with GraphPad 
Prism 2.01. for [3H]N,N(Me)2-Dmt-Tic-OH. 
G-proteins are activated by binding GTP. Hydrolysis of bound GTP to GDP terminates 
activation. Receptors activated by agonists catalyze the release of the inactive GDP as well as 
the binding of GTP, and thereby increase the relative level of G-protein activation. This effect 
can be inhibited by adding antagonists. [35S]GTPyS binding was performed [150] on 
membranes of the 5-receptor-rich frontal cortex of rat brain. Different concentrations of 
N,N(Me)2-Dmt-Tic-OH were incubated in the absence and presence of 1 pM Ile5,6deltorphin 
II, a potent 8-agonist. Incubations were carried out for 60 min at 30 °C. 
V 
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4. RESULTS AND DISCUSSION 
4.1 Synthesis 
The synthesis of Dmt was accomplished by literature methods [151] with some modifications. 
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Figure 2. Synthesis of ¿-Dmt and ¿)-Dmt 
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Racemic Dmt was synthesized from commercially available 3,5-dimethylphenol in a 
multistep reaction. The overall yield was 10.5%. Under our conditions, some problems were 
encountered. The first by-product formed on a larger scale was 0-carbethoxy-3,5-dimethyl-2-
chloromethylphenol during the Blank reaction. The ratio of the product and by-product 
depends on the HC1 flow rate, and the temperature presumably too has an important role. It is 
possible, that the amount of formaldehyde also influences the ratio of the products. The only 
way to remove this impurity was the recrystallization of diethyl acetamido-(2,6-dimethyl-4-
hydroxybenzyI)malonate from benzene. After decarboxylation to simplify the reaction route 
and the resolution of ¿-Dmt, acylase digestion was performed, but it was found that (DJL)-N-
acetyl-2',6-dimethyltyrosine was resistant to acylase I digestion. We therefore developed a 
new enzymatic method. 
Enzymatic digestion of N-TFA-Dmt resulted in good resolution. According to TLC 
and RP-HPLC, Carboxypeptidase A [152] can digest only the L enantiomer of N-TFA-Dmt in 
10 hours at 37 °C. According to the GC-MS assay after derivatization, the reaction yielded 
66% of an enantiomerically pure product. Esterification was performed with 3 M HC1 in 
isopropanol and followed by N-protection with trifluoroacetic anhydride. This reaction resulted 
in N-trifluoroacetyl-2,6-dimethyltyrosine isopropyl ester. The result revealed that the material 
contained 95.4% ¿-Dmt and 4.6% D-Dmt, . and the enantiomer excess was 91%. 
Unfortunately, recovery of the ¿>-Dmt was not really successful. The yield was much lower 
than before, the material contained 90.3% D-Dmt and 9.7% ¿-Dmt, and the enantiomer excess 
was 81%. 
Since our study required all stereoisomers of P-MeTyr, a rapid synthetic route 
involving Erlenmeyer condensation between hippuric acid and 4-methoxyacetophenone [153-
155] and resulting in racemates was chosen, rather than a stereoselective synthesis for each 
isomer. From the resulting 70/30 mixture of E- and Z-oxazolone, the E isomer was easily 
isolated by crystallization [156], £-Oxazolone can be isomerized to the Z isomer in pyridine 
[153], Further catalytic hydrogénation and subsequent deprotection steps afforded the erythro-
P-MeTyr and threo-P-MeTyr racemates. After Boc-derivatization both the erythro and threo 
P-MeTyr isomers were incorporated into the TIPP analogues [H] as racemic pairs. Peptide 
synthesis was performed by SPPS, using either a Merrifield resin or a 4-
methylbenzhydrylamine resin. The resulting epimeric peptides were characterized by RP-
HPLC, TLC and MS analyses (Tablé 3). The absolute configuration at the a-carbon of the P-
methyl-amino acid in each peptide was determined after acid hydrolysis and derivatization of 
the resulting amino acids with GITC or FDAA [157], 
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Figure 4. Possible side-chain conformations of S-Tyr and S-Phe 
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Table 2. Influence of the configuration of aromatic P-methyl amino-acids on the population of 
the side-chain 
(2S,3S) (2S,3R) (2R,3R) (2R,3S) 
gauche(~) ++ + + -
trans - + - + 
gauche(+) + - ++ ++ 
-, strongly disfavoured; +, allowed; ++, favoured 
Table 3. Physicochemical data on TIPP analogues 
Peptide 
HPLC 
k' 
TLC 
Rr 
MS 
Mol. wt. 
(4) (5) (7) 
H-TIPP-OH 3.9 0.65 0.82 0.53 635 
H-TIPP-NH2 3.23 0.71 0.88 0.62 634 
(SSVP-MeTyr'-TIPP-NHz 4.2 0.83 0.88 0.68 648 
(57?)-P-MeTyr1-TIPP-NH2 3.23 0.83 0.88 0.72 648 
(/U?)-P-MeTyr1-TEPP-NH2 4.3 0.71 0.89 0.78 648 
(Ä^-P-MeTyr'-TIPP-NHz 2.56 0.72 0.89 0.72 648 
(55)-P-MePhe3-TEPP-NH2 3.83 0.78 0.81 0.74 648 
(S/?)-P-MePhe3-Tn>P-NH2 3.23 0.78 0.81 0.71 648 
(/U?)-P-MePhe3-Tn>P-NH2 16.66 0.78 0.75 0.62 648 
(R5)-P-MePhe3-TIPP-NH2 14.76 0.75 0.79 0.61 648 
(S/?)-P-MePhe3-TIPP-OH 4.24a 0.77 0.82 0.69 649 
(/?5)-P-MePhe3-TIPP-OH 14.68a 0.77 0.88 0.55 649 
(55)-p-MePhe4-TIPP-NH2 4.43 0.77 0.79 0.7 648 
(5/?)-P-MePhe4-TIPP-NH2 8.5 0.76 0.76 0.67 648 
(/U?)-ß-MePhe4-TIPP-NH2 8.7 0.76 0.75 0.67 648 
(J?5)-ß-MePhe4-TIPP-NH2 3 0.75 0.82 0.76 648 
(5R)-P-MePhe3-DIPP-OH 4.78b 0.69 0.77 0.8 677c 
(J?5)-p-MePhe3-DIPP-OH 5.67b 0.67 0.74 0.78 677° 
(5J?)-P-MePhe3-I2-DIPP-OH 7.3 l
b 0.82 0.69 0.64 929° 
HPLC k' on a Vydac 218TP54 column; flow rate 1 cm3/min. Solvent system: 0.1% TFA in 
water, 0.1% TFA in ACN. Solvent front breakthrough at 3.0 min. 
Isocratic 27% organic component 
° Isocratic 30% organic component 
bGradient of25-60% organic component in 30 min; 
FAB ionization; CES ionization 
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Table 4. Capacity factors of GITC-derivatized amino acids 
GITC-AA k' 
Tyr 0.93 
Tic 1.61 
Phe 2.19 
L-threo-Q-MePhe 2.74 
D-threo-$- MePhe 3.26 
HPLC k' on a Vydac 218TP54 column; flow rate 1 cm3/min. Solvent system: 0.1% TFA in 
water, 0.1% TFA in ACN. Solvent front breakthrough at 2.8 min. 
Gradient of35-45% organic component in 30 min; 
Preparation of tritiated S-opioid antagonists 
Preparation of H-fH2J-Tyr-TicfCH2-NHJ-Cha-Phe-OH 
The precursor was prepared by a standard SPPS method, using Dit, described in the 
literature [IV]. 2.5 pmol of the iodinated precursor peptide was dissolved in 1 cm3 of DMF 
and 60 p.1 of 0.1 M TEA in DMF, 12 mg of Pd0/BaS04 was added as catalyst, and tritium gas 
was introduced. The reaction time was 80 min. The total radioactivity of the labelled peptide 
was measured by liquid scintillation counting, and was found to be 4.4 GBq (118.96 mCi). The 
crude tritiated peptide was. purified on reaction-zone type preparative TLC plates. It was found 
earlier that approximately 30-50 mCi of radioactivity can be conveniently purified in one run. 
The solvent system was acetonitrile-methanol-water (4:1:1). Radioactivity was detected by 
autoradiography of a photography emulsion, and the silica gel containing adsorbed radioactive 
material was then extracted with ethanol. This procedure resulted in pure material with a total 
activity of 1.44 GBq (39 mCi). The purity of the radiolabelled peptide was assessed by TLC, 
with detection of radioactivity by a TLC plate scanner in three different solvent systems, RP-
HPLC and a liquid scintillation detector. It was found that the tritiated compounds were pure 
and identical with the non-labelled parent compounds. The radiochemical purity was found to 
be at least 95%. The specific radioactivity of the purified [3H]TICP[VP] was 1.53 TBq/mmol 
(41.28 Ci/mmol). This specific radioactivity was high enough to perform biological tests. This 
was not the theoretical maximum, which could be a result of hydrogen impurity in the tritium 
gas or exchange reactions with labile protons of the reagents, the target compound, the 
solvent, etc. The tritiated compound was stored as a 37 MBq/cm3 ethanolic solution under 
liquid nitrogen. 
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Preparation of H-fH2]-Tyr-Tic[CH2-m]-N(Me)Phe-Phe-OH 
The precursor was prepared by a standard SPPS method, using Dit. 2.5 pmol of the 
iodinated precursor peptide was dissolved in 1 cm3 of DMF and 1 pi TEA, 10 mg of 
PdO/BaSC>4 was added as catalyst, and tritium gas was introduced. The reaction time was 70 
min. The total radioactivity of the labelled peptide was measured by liquid scintillation 
counting, and was found to be 3.56 GBq (95.96 mCi) The crude tritiated peptide was purified 
on reaction-zone type preparative TLC plates using an acetonitrile-methanol-water (4:1:1) 
solvent system. The purity of the radiolabeled peptide was assessed by TLC, with detection of 
radioactivity by a TLC plate scanner in three different solvent systems, RP-HPLC and a liquid 
scintillation detector. The radiochemical purity was found to be at least 95%. The specific 
radioactivity of the purified [3H]N(Me)Phe3TIPP[vF] was 1.06 TBq/mmol (28.65 Ci/mmol). 
The tritiated compound was stored as a 37 MBq/cm3 ethanolic solution under liquid nitrogen. 
Preparation ofH-[3 \5 '-H]Dmt-Tic-OH 
The synthesis of H-[3',5'-I2]-Dmt-Tic-OH has been described in the literature [I]. To a 
solution of 2.5 pmol of precursor in 1 cm3 of DMF, 12 mg of Pd0/BaS04 and 0.8 pi of TEA 
were added, and tritium gas was introduced. The reaction time was 80 min. The total 
radioactivity of the radiolabeled peptide was measured by liquid scintillation counting, and 
proved to be 3.96 GBq (107 mCi). The crude tritiated peptide was purified by RP-HPLC. 
During tritiation, diketopiperazine formation was observed, with k' = 12.7. The purity of the 
radiolabeled peptide was assessed by RP-HPLC, and was found to be at least 95%. After 
purification, 1.6% of diketopiperazine was found. During storage in methanol, this value 
increased to 18.9% at 24 hours. The amount of peptide was determined by UV spectrometry, 
using unlabeled TFAxH-Dmt-Tic-OH as a standard (e = 29.74 dm3/mmol><cm at 214 nra) 
[29 740 cm2/mmol]. The specific activity of the purified H-[3H]Dmt-Tic-OH was 
1.65 TBq/mmol (44.67 Ci/mmol). The purified peptide was stored in a concentration of 18.5 
MBq/cm3 (0.5 mCi/cm3) in methanol/water 1:4, with the pH adjusted to 9 with NH4OH, and 
with the solution under liquid nitrogen. 
Preparation ofN,N(Me)2-[3\5 '-3H]Dmt-Tic-OH 
The synthesis of N,N(Me)2[3',5'-l2]-Dmt-Tic-OH has been described in the literature 
[I]. To a solution of 2.5 pmol of the precursor in 1 cm3 of DMF, 12 mg of Pd0/BaS04 as 
catalyst and 0.9 pi of TEA were added, and tritium gas was introduced. The reaction was 
completed in 80 min. The total radioactivity of the tritiated peptide was measured by liquid 
scintillation counting, and proved to be 2.96 GBq (80 mCi). The crude tritiated peptide was 
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purified by RP-HPLC. The amount of peptide was determined by UV spectrometry, using 
unlabelled TFAxN,N(Me)2-Dmt-Tic-OH as a standard (e = 30.92 dm3/mmolxcm at 214 nm) 
[30 920 cm2/mmol]. The specific activity of the purified N,N(Me)2-[3H]Dmt-Tic-OH was 
2.22 TBq/mmol (59.88 Ci/mmol). The purified peptide was stored in a concentration of 
18.5 MBq/cm3 (0.5 mCi/cm3) in acetonitrile/water 1:4 under liquid nitrogen. 
Preparation of H-fH2]-Tyr-Tic-(L)-threo-P-MePhe-Phe-OH 
The precursor was prepared by a standard SPPS method, using Dit. 1.7 pmol of the 
iodinated precursor peptide was dissolved in 1 cm3 of DMF, 5.5 pi of 10% TEA in DMF and 
10.5 mg 0fPd0/BaS04 as catalyst were added and tritium gas was introduced. The reaction 
time was 85 min. The total radioactivity of the labelled peptide was measured by liquid 
scintillation counting, and was found to be 3.92 GBq (106 mCi). The crude tritiated peptide 
was purified by RP-HPLC. The purity of the radiolabeled peptide was assessed by RP-HPLC 
and a liquid scintillation detector. The radiochemical purity was found to be at least 95%. The 
quantity of the purified labelled material was determined by HPLC, using a calibration curve. 
The specific radioactivity of the purified [3H]-(L>//jreo-p-MePhe3-TIPP was 1.99 TBq/mmol 
(53.7 Ci/mmol). The tritiated compound was stored as a 37 MBq/cm3 ethanolic solution under 
liquid nitrogen. 
Preparation of H-fH2]-Tyr-Tic-(D)-threo-P-MePhe-Phe-OH 
The precursor was prepared by a standard SPPS method, using Dit. 1.65 pmol of the 
iodinated precursor peptide was dissolved in 1 cm3 of DMF, 5.5 pi of 10% TEA in DMF and 
12.3 mg of PdO/BaSCL as catalyst were added and tritium gas was introduced. The reaction 
time was 100 min. The total radioactivity of the labelled peptide was measured by liquid 
scintillation counting, and was found to be 3.17 GBq (85.75 mCi). The crude tritiated peptide 
was purified by RP-HPLC. The purity of the radiolabeled peptide was assessed by RP-HPLC 
and a liquid scintillation detector. The radiochemical purity was found to be at least 95%. The 
quantity of the purified labelled material was determined by HPLC, using a calibration curve. 
The specific radioactivity of the purified [3H]-(Z)J-//ireo-p-MePhe3-TIPP was 2.09 TBq/mmol 
(56.5 Ci/mmol). The tritiated compound was stored as a 37 MBq/cm3 ethanolic solution under 
liquid nitrogen. 
lodination of H-Dmt-Tic-(L)-threo-$-MePhe-Phe-OH 
2.5 pmol of peptide was dissolved in 100 pi of ACN/water (1:1) and 4 equivalents of 
Nal (10 mg/cm3 ACN/water solution) and 4 equivalents of chloramine-T (10 mg/cm3 
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ACN/water solution) were added. After stirring for 300 s at RT, the products were separated 
by HPLC to give the desired diiodinated peptides in 70-75% yield. Purified I2-Dmt-containing 
precursor peptides were characterized by HPLC and MS analyses. 
Preparation of H-[3H2]-Dmt-Tic-(L)-threo-$-MePhe-Phe-OH 
0.62 ixmol of the iodinated precursor peptide was dissolved in 1 cm3 of DMF and 3 pi 
of 10% TEA in DMF, 10 mg of Pd/BaS04 was added as catalyst and tritium gas was 
introduced. The reaction time was 80 min. The total radioactivity of the labelled peptide was 
measured by liquid scintillation counting, and was found to be 0.86 GBq (23.28 mCi). The 
crude tritiated peptide was purified by RP-HPLC. The purity of the radiolabeled peptide was 
assessed by RP-HPLC and a liquid scintillation detector. The radiochemical purity was found 
to be at least 95%. The quantity of the purified labelled material was determined by HPLC, 
using a calibration curve. The specific radioactivity of the purified [3H]-(L,)-i/ira>-P-MePhe3-
DIPP was 2.15 TBq/mmol (58.06 Ci/mmol). The tritiated compound was stored as a 18.5 
MBq/cm3 ethanolic solution under liquid nitrogen. 
Table 5. Physicochemical data and specific rac ioactivities of labelled peptides 
Peptide 
HPLC 
k' 
TLC 
Rr 
TBq/mmol 
Specific 
radioactivity (4) (5) (6) 
r3H1TICPr*Fl 12 0.62 0.49 0.66 1.53 
r3Hl-N(Me)Phe3-TIPPm 8.1 0.63 0.55 0.68 1.06 
H-[3H]Dmt-Tic-OH 10.2" — — — 1.65 
N,N(Me)2-[3H]Dmt-Tic-OH 8. Ie 0.5 0.29 0.53 2.22 
r3HML)-//ira>-ß-MePhe3-TIPP 5.6d 0.77 0.82 0.75 1.99 
r3Hl-(D)-i/ireo-ß-MePhe3-TIPP 6.51" 0.77 0.88 0.72 2.09 
r3Hl-(L)-i/>ra>-ß-MePhe3-DIPP 5.94d 0.69 0.77 0.76 2.15 
HPLC k'on a Merck 50943 LiChroCart 125-4 LiChrospher 100 RP-18 column; flow rate 1 
cm3/min. Solvent system : 0.1% TFA in water, 0.1% TFA in ACN. Solvent front breakthrough 
at 1.2 min. 
Gradient of25-50% organic component in 30 min 
bGradient program: at 0 min 15%, at 10 min 20%, at 15 min 32% and at 25 min 50% organic 
component 
cGradient program: at 0 min 20%, at 10 min 30% and at 15 min 40% organic component 
. dVydac 218TP54 column; Solvent front breakthrough at 2.85 min. 
Gradient of 15-70% organic component in 30 min 
Under the TLC conditions, the short piperazine formation made it impossible to determine the 
Rf of H-[3H]Dmt-Tic-OH. 
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4.2. Biological data 
4.2.1. fi-Methyl amino acid substituted TIPP analogues 
The new TIPP analogues were examined with regard to their binding properties to rat 
brain opioid receptors and their in vitro bioactivities, via their abilities to inhibit an electrically 
induced contraction of the MVD or GPI. 5-Antagonist potencies were determined against 
agonist DPDPE. 
For the characterization of P-methyl amino acid substituted TIPP analogues, 
[3H]DPDPE was used as 6-, [3H]sufentanil as p- and [3H]U-69593 as K-radioligand, 
respectively. The binding affinities of these ligands are summarized in Table 6. 
5-Opioid antagonists may be useful therapeutic agents in analgesia in combination with 
p-agonists such as morphine, or the development of a single opioid compound acting as an 
agonist at the p-receptor and as an antagonist at the 5-receptor, might be of benefit in the 
management of chronic pain. The modification of TEPP-NH2, a mixed p-agonist/8-antagonist, 
served to find an analgesic with a low propensity to produce analgesic tolerance and physical 
dependence. 
Table 6. Receptor binding affinities of TIPP analogues containing P-methyl amino acids 
Peptides K¡ (nM) ± SEM 
H-TIPP-OH >10 000 0.4810.07 >10 000 
H-TIPP-NH2 178±26 0.8310.11 8381116 
(55)-P-MeTyr1-TIPP-NH2 3521100 2.8810.25 >10 000 
(S/?)-3-MeTyr1-TIPP-NH2 284163.5 1.2110.06 >10 000 
(ft/?)-3-MeTyr1 -TIPP-NH2 1 5961412 2812 1 180163.5 
(R5)-3-MeTyr,-TIPP-NH2 >10 000 113114 2 5091300 
(<SSy3-MePhe3-TIPP-NH2 9731309 2.9110.4 3 3961655 
(5ft)-3-MePhe3-TEPP-NH2 149131 0.6610.07 432411978 
(ftft)-3-MePhe3-TIPP-NH2 >10 000 7415.1 442152 
(RS)- 3-MePhe3-TIPP-NH2 84121 0.510.07 1 1901452 
(5/2)-3-MePhe3-TIPP-OH >10 000 0.3810.01 >10 000 
(/?5)-3-MePhe3-TIPP-OH 8101185 0.7610.10 >10 000 
(SS)-3-MePhe4-TIPP-NH2 47112.4 1.610.18 1 282187 
(5,R)-3-MePhe4-TIPP-NH2 2 0211202 1.6810.15 253110 
(ftft)-3 -MePhe4-TIPP-NH2 4981150 4.110.3 766118 
(RS)-3 -MePhe4-TEPP-NH2 >10 000 1111.01 2 8441519 
H f3H]sufentanil (rat forebrain), 8b: I3H]DPDPE (NxG 108 CC 15 cells), k c: fHJU-
69593 (guinea pig cerebellum) 
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The L-P-methyl amino acid containing TIPP analogues [II] displayed only slight 
changes in 8-receptor affinity as compared with the parent peptides TIPP or TIPP-NH2. The 
effect of change of the configuration at the P-carbon on the 8-receptor binding was found to be 
small. The p-receptor affinity was influenced to a larger extent, particularly as concerns the 
residue at position 4. 
In the .D-P-methyl amino acid containing TIPP analogues, the effects were more 
dramatic. The replacement of Tyr1 resulted in new compounds, the (2R,3R) conformer proving 
more potent than the (2R,3S). This was in contrast with P-MePhe3-TIPP, where the (2R,3R)~ 
P-MePhe3 analogue displayed a 10 times lower 5-affinity than its corresponding parent peptide 
and no p-receptor affinity, and the epimeric (2R,3S) compound exhibited subnanomolar 8-
receptor affinity. It was expected, that replacement of the C-terminal carboxamide function in 
(2/?,3S)-P-MePhe3-TIPP-NH2 by a carboxylic acid group would lead to a new compound with 
enhanced 5-receptor selectivity. The P-MePhe4 substitution resulted in the still quite potent and 
5-receptor selective ligands. The K-receptor binding remained low in all cases. 
In the MVD and GPI assays [II], all compounds of the Z,-P-methyl amino acid 
containing series retained 5-antagonist properties with the exception of the partial agonist 
(25,3/?)-p-MeTyr1-TEPP-NH2. The results are summarized in Table 7.The 8-antagonist 
properties in general correlated with the values obtained in experiments on the S-receptor 
affinity. The analogue (2S, 3/?)-P-MePhe3-TIPP had a very high 5-antagonist potency, with no 
p-antagonist and p-agonist properties. The P-MePhe4-TIPP-NH2 analogues were mixed p-
agonist/5-antagonists, with nearly the same properties as those of TEPP-NH2- (2S,3S)-P-
MePhe4-Tn>P-NH2 was a better p-agonist; it had a smaller K« value than the parent peptide, 
and it might be a promising ligand for the treatment of pain. 
In the £>-P-methyl amino acid containing TIPP analogue series, P-MeTyr1 replacement 
resulted in weakly potent 5-antagonists, in agreement with their low 8-receptor affinities. 
Interestingly, the analogue (2J?,3J?)-P-MePhe3-TIPP-NH2 was a moderately potent, but quite 
selective 5-antagonist, while the epimer (2/?,35)-P-MePhe3-TIPP-NH2 was a very potent full 8-
agonist with a moderately potent p-agonist potency. The corresponding peptide with a carboxy 
terminal had partial agonist properties at both receptors. The P-MePhe4 analogues maintained 
moderate 5-antagonist potencies, whereas the (2/?,3/?)-p-MePhe4 analogue was a partial p-
agonist, and (2/?,35)-P-MePhe4-TIPP-NH2 was a very weak, but full p-agonist 
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Table 7. Activities in MVD and GPI bioassays of TIPP analogues containing P-methyl amino 
acids 
Peptides 
Bioa issav 
G P I ( ICso) ± S E M 
agonist TnM] 
MVD (Ke DPDPE) 1 SEM 
antagonist [nMl 
H-TIPP-OH > 1 0 0 0 0 4 . 8 1 0 . 2 
H-TIPP-NH2 1 7 0 0 ± 2 2 0 1 8 1 2 . 2 
(SS)-P-MeTyr1-TIPP-NH2 > 1 0 0 0 0 1 0 2 1 6 
(S/O-p-MeTyr'-TIPP-NHi 1 2 1 0 ± 2 6 0 IC25 = 1 0 3 0 1 1 2 0 part, a yon. max. 50% 
(R/f)-P-MeTyr1-TIPP-NH2 > 1 0 0 0 0 1 0 2 0 1 1 5 0 
(/?5)-P-MeTyr1-TIPP-NH2 > 1 0 0 0 0 3 1 7 1 6 2 
(SS)-p-MePhe3-TIPP-NH2 5 5 2 0 1 6 4 0 1 8 . 2 1 3 . 4 
(5R)-P-MePhe3-TIPP-NH2 5 0 8 0 1 7 0 0 7 . 2 4 1 0 . 1 1 
(£/?)-p-MePhe3-TEPP-NH2 > 1 0 0 0 0 5 4 . 4 1 5 . 8 
(R5)-p-MePhe3-TIPP-NH2 1 2 7 1 1 9 IC50 = 1 . 7 8 1 0 . 2 5 agonist 
(SK)-P-MePhe3-TIPP-OH > 1 0 0 0 0 0 . 1 9 2 1 0 . 0 2 5 
(RS)-P-MePhe3-TIPP-OH IC35 = 5 1 9 1 6 2 pan. aeon. max. 70% IC30 = 0 . 6 2 3 1 0 . 1 2 part. agon. max. 60% 
(55)-p-MePhe4-TIPP-NH2 6 3 6 1 6 2 5 . 3 6 1 1 . 0 5 
(S/?)-p-MePhe4-TIPP-NH2 2 7 4 9 1 3 6 0 5 . 3 7 1 0 . 8 4 
(RR)-p-MePhe4-TIPP-NH2 IC35 = 1 7 1 0 1 2 7 0 cart. aeon. max. 70% 2 0 . 5 1 0 . 7 
(/?5)-p-MePhe4-TIPP-NH2 4 5 1 0 1 7 5 0 2 7 . 7 1 5 . 5 
The intramolecular distance between the aromatic rings of Tyr1 and Tic2 is an important 
factor determining the ¿-antagonism in TIP(P). The aromatic rings of Phe3 and Phe4 may 
prevent the hydrophobic collapse of the Tyr-Tic rings and can engage in additional receptor 
interactions. The introduction of a P-methyl group on each of the residues may therefore have 
effects on the receptor affinity, on the selectivity and on the agonist/antagonist character, by 
biasing the side-chain topology. In general, it was clear that the introduction of ¿-P-methyl 
amino acids in TIPP [II] had an unimportant effect on the 8-receptor affinity and on the 8-
antagonist potency. Both of the P-MeTyr1 isomers allowed a gauche(-) conformation, which 
was not consistent with the theoretical models of the Tyr-Tic dipeptide analogue [158], For P-
MePhe3, the threo isomer-containing peptide was more potent than its erythro analogue. This 
indicated that a trans was preferred, and a gauche(+) conformation'was out of the question 
as a bioactive conformation. In the lowest-energy conformation of TEPPpF], the Phe3 assumed 
the trans orientation, which made it more exposed and accessible for the interaction with the 8-
receptor [79], The receptor selectivity was further increased in (2S,3R)-p-MePhe3-TIPP-OH, 
and the high potency confirmed the previous conclusion. This compound had a K«. value of 
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0.192 nM, which was comparable to those of the most potent 8-antagonists, such as TICP[T], 
DIPP and N,N-(Me)2Dmt-Tic-OH. In the p-MePhe4-TIPP-NH2 analogues, the configuration 
of the P-carbon had little effect on the 5-receptor affinity and potency. This can be explained 
by the fact that both of the isomers can exist in the gauche(-) instead of the trans 
conformation. The difference between the isomers was more stressed in the case of the p-
affinity; this resulted in the higher S-selectivity of the (2S',3/?)-P-MePhe4-TIPP-NH2 ligand. 
Some important effects can be observed in the D-P-methyl amino acid containing series. Since 
the D-Tyr1 residue is not tolerated in opioid peptides, the low potency was not surprising in 
these analogues. An interesting observation was made in the case of the D-P-MePhe3 peptides. 
While the (2/2,3/2)-P-MePhe3-TIPP-NH2 analogue retained an antagonist character, the epimer 
with the (2/?,35) configuration proved to be a very potent 5-agonist and a moderately potent 
p-agonist. It was supposed that the XI-rotamer, which was highly disfavoured in the (2/2,3/?) 
isomer, but existed in the other isomer, can cause this effect. Change of the C-terminal amide 
to the carboxylic acid in (2/?,35)-P-MePhe3-TIPP-NH2 resulted in a new compound with 
partial 5-agonism. The effect of D-P-MePhe4 substitution was similar to that, in the case of the 
¿-amino acid. Both compounds retained moderate 5-antagonism, but in (2/2,3/?)-P-MePhe4-
TIPP-NH2 partial p-agonism was observed. 
4.2.2. Binding characteristics of fH]TlCP[¥J and fH]N,N(Me)2-Dmt-Tic-0H 
This work was Carried out by the Receptor Research Group of BRC. 
The results of the binding kinetics experiments indicated [IV], that a steady state was 
reached in 60 min. with [3H]TICP[VF] (0.5 nM) at 25 °C (Figure 5). The determined 
association rate constant was 1.2 106 sec^M"1 and the dissociation rate constant was 5.6 10"4 
sec"1. From these rate constants, a binding K¿ of 0.47 nM was calculated. 
The binding of [3H]N,N(Me)2-Dmt-Tic-OH [V] was rapid, a steady state being reached 
after 25 min of incubation at 25 °C. 
For estimation of the total and non-specific binding, increasing concentrations of 
[3H]TICP[VF] and [3H]N,N(Me)2-Dmt-Tic-OH were incubated with membranes in the absence 
and presence of 10 pM naloxone. 
Saturation binding experiments on [3H]TICP[*F] [IV] were performed with the 
radiolabeled ligand by varying the concentration over the range from 0.02 nM to 3 nM. The 
specific binding was found to be saturable. The Seatchard plot (Figure 6) was used to evaluate 
the data, and this indicated the existence of a single binding site with a K¿ of 0.35±0.03 nM, a 
value in reasonable agreement with the Kd obtained from the binding kinetics experiments. The 
maximum number of binding sites was 112.1±9.6 fmol/mg protein. 
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Figure 5. Association and dissociation curves of [3H]TICP[VF] binding to rat brain membranes 
at 25 °C 
Free Concentra t ion (nM) 
Figure 6. Saturation binding curve and Scatchard plot (insert) of [3H]TICP[lF] binding to rat 
brain membranes. Plots on graph represent specific binding. 
The specific binding of [3H]N,N(Me)2-Dmt-Tic-OH [V] was also saturable and 
Scatchard analysis (Figure 7) of the saturation binding data was best fitted with a single 
binding site model. K<j and the maximum number of binding sites were determined and found to 
be 0.42 ± 0.03 nM and 63.12 ± 1.22 fmol/mg protein, respectively. 
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Figure 7. Saturation binding curve and Scatchard plot (insert) of [3H]N,N(Me)2-Dmt-Tic-OH 
binding to rat brain membranes. Plots on graph represent specific binding. 
Equilibrium competition experiments were performed with the use of various unlabelled 
ligands selective for p.-, 5- or K-receptors to displace bound [3H]TICP[VP] The rank order of 
potency within the series of compounds tested was 5 » K > p (Table 8). The determined K¡ 
values indicate that TICPfT] has a higher affinity for 5-receptors than all the used unlabelled 
ligands. In similar experiments, the inhibition of the binding of [3H]N,N(Me)2-Dmt-Tic-OH by 
various unlabelled specific opioid ligands was studied (Table 8). The rank order of potencies 
was found to be 5 » p « k. The reported K¡ values indicated that naltribene and naltrindole 
had the highest affinities for the 5-receptor. The results also confirmed that N,N(Me)2-Dmt-
Tic-OH bound to the 5-receptor with a high affinity comparable with that of naltrindole, and 
more tightly than TIPPfT'] 
For both radioreceptor binding and localization studies, there were a number of 
requirements that a labelled compound had to fulfil: most importantly a low amount of non-
specific binding, reaching of the steady state in a feasible time, a high specific radioactivity and 
a high selectivity. The high amount of non-specific binding was the problem, for example, with 
H-Tyr-Tic[CH2-NH]-N(Me)Phe-Phe-OH. [3H]TICP[VP] and [3H]N,N(Me)2-Dmt-Tic-OH fulfil 
all of these criteria. Both of our new tritiated ligands had high specific radioactivities. The ratio 
of non-specific binding was about 45-50% for [3H]TICP[VF] (Table 9), and the specific binding 
reached a steady state in approximately 60 min. The conclusion from this work is that 
[ 3 H]TICP[ V P] is a radioligand with high 5-receptor affinity and unprecedented 5-receptor 
selectivity. TICPfT] proves to be a very convenient ligand for investigation and identification 
of the 5-opioid receptor. The non- specific binding of [3H]N,N(Me)2-Dmt-Tic-OH was around 
10-15%, while the specific binding reached a steady state in approximately 25 min. As for 
specificity, [3H]N,N(Me)2-Dmt-Tic-OH is an exceptionally 5-specific ligand. The differences 
between the affinities of the subtypes of the 5-receptor resulted in differences in the Bmax values 
of these ligands. Measurement of the K¡ values of [3H]N,N(Me)2-Dmt-Tic-OH against a 
41 
number of 5-specific opioid ligands in radioreceptor binding assays revealed that the inhibition 
constants were in the subnanomolar or the low nanomolar range and the lowest Ki value was 
measured against naltrindole; this was even lower than that against N,N(Me)2-Dmt-Tic-OH 
itself. This extraordinarily low Ki value might be due to the conformational similarities between 
this opioid dipeptide and naltrindole. TEPP[T/] gave a K; value close to 1 nM. Interestingly, 
despite the high sequence similarities, its parent compound, TIPP, gave the highest Ki values 
among all the 5-compounds. We can conclude that the dipeptide [3H]N,N(Me)2-Dmt-Tic-OH 
is one of the most specific and potent 5-radioligands available for characterization of the 8-
opioid receptor in in vitro and in vivo studies. 
Table 8. Inhibition of ^HJTICPtT1] and [3H]N,N(Me)2-Dmt-Tic-OH binding by various opioid 
receptor-selective ligands 
Unlabelled ligand Type Ki±SEM (nM)a Kil SEM (nM)b 
lie5,6 Deltorphin II 5 1.54±0.85 3.3910.47 
Deltorphin II 5 2.48±0.22 0.2810.07 
Naltrindole 5 0.6110.19 0.1410.001 
DSLET 5 3.3510.4 2.1010.15 
DPDPE 5 10.4712.51 1.9110.55 
TEPP 8 4.6213.2 16.2313.76 
TIPPM 8 2.4910.9 1.3110.12 
Naltribene 5 — 0.0210.01 
T I C P m 5 0.3510.03 — 
N,N(Me)2-Dmt-Tic-OH 8 — 0.4410.13 
Dermorphin M — 569.671289.2 
DAMGO M 416.5116 1 053.21216.8 
Dihydromorphine M 126.9120.8 — 
Levorphanol M 5.4510.75 8.1010.69 
Dextrorphan M > 10 pM > 10 pM 
Endomorphin 1 M — 20 046.67112 894.7 
Endomorphin 2 M — 2 580.3311 137.9 
U69593 K 331.291194.58 5 964.001609 
Nor-binaltorphimine K 46.317.6 — 
EKC K — 660.191117.66 
Dynorphin A (1-11) K — 269.07165.81 
fHJTICPtW],b, l3H]N,N(Me)2-Dmt-Tic-OH 
Table 9. Changes in the non-specific binding values of tritiated ligands 
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TIPP TIPP[VP] TICP[VP] N,N(Me)2-Dmt-Tic-OH 
Non-specific 
binding 
35% 30% 45-50% 10-15% 
It was further concluded that both of our new tritiated ligands were about 10 times more 
potent than TIPP or TIPP[XP] (Table 10). Moreover, it was important that TICPfT] and 
N,N(Me)2-Dmt-Tic-OH were very stable against chemical degradation under storage 
conditions, and against enzymatic degradation under binding conditions 
Table 10. Kd anc Bmax values of tritiated ligands based on Scatchard analysis and K^ values 
Analogues TIPP TIPPfT*] TlCPf1?] N,N(Me)2-Dmt-Tic-OH 
Bmai fmol/mg 82.4±20.4 105.5±49 112.4+7.5 63.12 ± 1.22 
K<j (nM) 0.64±0.20 0.98±0.12 0.35±0.03 0.42 ±0.03 
Ke (nM) 4.8a 2.89a 0.219a 0.28b 
a ref. 159, "ref. 75 
The antagonist property of the peptide, shown previously in MVD tests, was further confirmed 
here by a biochemical approach, [35S]GTPyS binding. As shown in Figure 8, N,N(Me)2-Dmt-
Tic-OH potently and effectively reversed the activation of GTP-binding proteins by a specific 
5-agonist peptide, Ile5'6deltorphin II, as measured by the binding of the non-hydrolysable GTP 
analogue, GTPyS. The ED50 value of this effect was in the nanomolar range (8 .1 nM), which 
emphasizes the potential usefulness of this molecule 
160-
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Figure 8. Inhibition of agonist-stimulated [35S]GTPyS binding by N,N(Me)2-Dmt-Tic-OH in 
membranes of rat frontal cortex. Grey bars mean the absence and black bars mean the presence 
of 1 pM Ile5,6deltorphin II. Non-specific binding was 61%; non-stimulated [35S]GTPyS binding 
was 67.3 ±11 .6 fmol/mg protein. Points are means ± S.E.M. of data from three independent 
experiments carried out in triplicate. 
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5. SUMMARY 
Our aim was the develolopment of a new 5-antagonist or a mixed p-agonist/5-
antagonist from the TIPP family. The idea was based on the peptide library: a slightly 
constrained, P-methyl amino acid substitution on each position of TIPP or TIPP-NH2. To 
reach our aims, we achieved the following results: 
• We performed the Erlenmeyer condensation between hippuric acid and 4-
methoxyacetophenone to gain P-MeTyr. 
• Both the erythro and threo P-MeTyr isomers were incorporated into the TIPP analogues 
and the resulting epimeric peptides were characterized by RP-HPLC, TLC and MS, 
separated and purified by RP-HPLC. The absolute configuration at the a-carbon of the P-
methyl-amino acid in each peptide was determined after acid hydrolysis and derivatization 
of the resulting amino acids with GITC. 
• We performed the racemic synthesis of Dmt and developed a new enzymatic resolution 
method. 
We found that there were crucial effects on the receptor selectivity and on the 
agonist/antagonist character following the introduction of P-methyl amino acids. Tyr-Tic was 
previously found to be the first opioid peptide without Phe that had 5-opioid selectivity and 
antagonist bioactivity. The presented work confirmed that substitution at Phe3 and Phe4 can 
strongly influence'the profile of biological properties. Despite the fact that a single P-methyl 
substituent is reported not to constrain the side-chain position of aromatic amino acids 
extensively, it was revealed that these topographically constrained amino acids resulted in 
differences in biological activity in the TIPP series. These results were hard to explain in terms 
of the topographical requirements of the receptor as concerns the side-chain conformations. 
New, larger substituents with higher energy differences between the rotamers may provide 
additional information about this question. 
We have obtained some promising ligands, such as (2S,3ft)-P-MePhe3-TIPP-OH, 
which exhibited subnanomolar 8-receptor affinity and the K<. value of which was comparable to 
those of TlCPt^P] and N,N(Me)2-Dmt-Tic-OH. Another result was the development of 
(25,35)-P-MePhe4-TIPP-NH2, which had a better p-agonist property and was a more potent 5-
antagonist than the parent TBPP-NH2, and might be a candidate ligand for the treatment of pain 
or to serve as a basis for further development. 
We synthesized the tritiated ligands for radioreceptor binding. With this work, we 
wished to develop a series of ô-antagonist radioligands suitable for any receptor binding 
conditions. It had been reported previously that TICPf^F] and N,N(Me)2-Dmt-Tic-OH were 
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good 5-antagonist candidates for tritium labelling. We chose some promising 5-antagonist 
ligands from our former work and made them in radiolabelled form. Unfortunately, the 
biological characterization of these TIPP analogues has not yet been completed. We have 
prepared the following tritiated analogues: 
• [3H]TICP[*F] 
• [3H]-N(Me)Phe3-TIPP[vP] 
• H-[3H]Dmt-Tic-OH 
• N,N(Me)2-[3H]Dmt-Tic-OH 
• [3H]-(L;-//ireo-P-MePhe3-TIPP 
• [3H]-(D>//i/-eo-3-MePhe3-TIPP 
• [3H]-(L>/W-3-MePhe3-DIPP 
The radioreceptor binding studies revealed that both [3H]TICP[»P] and N,N(Me)2-
[3H]Dmt-Tic-OH were suitable for 5-receptor characterization. They had high specific 
radioactivity, they were very stable against chemical and enzymatic degradation under storage 
and binding conditions, they had low ratio of non-specific binding (even N,N(Me)2-[3H]Dmt-
Tic-OH), both had a very high ô-receptor affinity and unprecedented 8-receptor selectivity, and 
the specific binding reached a steady state in a feasible period of time. The most important 
conclusion was that both of our new ligands were 10 times more potent 5-antagonists than 
TlPPf^P]. All these parameters made them very convenient ligands for investigation and 
identification of the 5-opioid receptor. It is important to emphasize that the H-Dmt-Tic-OH 
sequence represents the minimum sequence of the 5-antagonism to date, and this statement 
gives peculiar importance to N,N(Me)2-[3H]Dmt-Tic-OH radioligand. 
[3H]-(Z)-//?^o-P-MePhe3-TIPP is also a veiy potent 5-antagonist with a subnanomolar 
Ke value, and it was known from earlier results that [3H]T1PP has a lower non-specific binding 
than [3H]TICP[VF], Replacement of Tyr1 with Dmt in (Z,>//weo-P-MePhe3-TIPP may produce 
further enhancement of the 5-antagonist potency, but also a slight decrease in 5-receptor 
selectivity. The resulting labelled peptide [3H]-(£)-//ireo-3-MePhe3-DIPP may be the most 
potent 5-receptor antagonist. We hope that these new ligands can fulfil all criteria of 
radioligands and can prove to be useful research tools. 
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